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I. Abstract  
Physical inactivity and sedentary time: impact on metabolic health and 
development of type 2 diabetes 
Kelly Anne Bowden Davies 
Physical inactivity is a major risk factor for global mortality; it is associated with the 
development of obesity, metabolic syndrome (MetS), non-alcoholic fatty liver disease 
(NAFLD), type 2 diabetes (T2D) and cardiovascular disease (CVD). Despite the 
worldwide recommendations and health guidelines recommending an active lifestyle, 
low levels of physical activity (PA) and sedentary behaviour are increasingly prevalent 
in modern society. The primary aim of this thesis is to examine the role of sedentary 
time and physical inactivity with a specific emphasis on the development of multi-
organ insulin resistance as precursor for the development of T2D.  
The initial data within this thesis provided evidence for the importance of a physically 
active lifestyle irrespective of obesity. Ninety-eight individuals were recruited, 
screened, identified as free from disease and subsequently categorised according to 
obesity status and MetS (termed herein unhealthy). Seventy-three individuals were 
non-obese, of which 11 were unhealthy, and 25 individuals were obese, of which 13 
were unhealthy. PA did not fully explain metabolic health status but sedentary time 
was higher in obese individuals. Secondary data in this cohort revealed an independent 
association between sedentary time and liver fat, which is a proxy for poor metabolic 
health and clinical manifestations related to T2D. Of note, moderate-vigorous physical 
activity, which is the cornerstone of PA recommendations, did not significantly 
influence metabolic health, obesity or liver fat. Research examining the consequences 
of a physically inactive lifestyle (i.e. sedentary behaviour) is warranted. 
The major data detailed within this thesis were derived from inducing short-term 
physical inactivity in first-degree relatives (FDR) of patients with T2D, compared with 
healthy controls (CON). Forty-five habitually active participants (16 FDR, 29 CON) 
were assessed at baseline, after 14 days of inactivity and after 14 days of resuming 
normal activity. Sedentary time increased in parallel with a decrease in PA during the 
period of inactivity. Cardiorespiratory fitness reduced, lower limb lean mass 
decreased, while gynoid fat increased and significantly more android fat was 
accumulated in FDR. Significant increases in liver fat were accompanied by increased 
plasma triglycerides, which were increased to a greater extent in FDR. Whole body 
insulin sensitivity significantly with no difference between the groups. Resumption of 
normal activity reversed all observed changes. FDR seem susceptible to some of the 
the risks of physical inactivity.  
Taken together, these data support the importance of reducing physical inactivity and 
sedentary time. FDR have an increased risk of developing T2D compared with CON 
and therefore these data must be used as a platform to develop guidelines and strategies 
aimed at preventing chronic physical inactivity and sedentary behaviour, particularly 
in these individuals. Considering linked epidemics of T2D and physical inactivity, 
innovative strategies must be developed to promote the importance of a habitually 
active lifestyle, either as a minimum or in addition to current guidelines.  
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Introduction  
The global prevalence of diabetes has risen from 108 million in 1980 to 422 million in 
2014 (WHO, 2016) and is projected to continue rising (Mathers and Loncar, 2006). 
Approximately 5 million people in England are at a high risk of developing the disease, 
which can lead to a number of other health problems including cardiovascular disease 
(CVD), stroke, nephropathy, neuropathy, limb amputation and blindness (PHE, 2016). 
Type 2 diabetes (T2D) accounts for the majority of people with diabetes and is largely 
related to excess body weight (overweight and obesity) and physical inactivity. If 
current trends persist, one in three people will be obese by 2034 and one in ten will 
develop T2D (Diabetes UK, 2016). The total financial cost (direct care and indirect 
costs) associated with diabetes in the UK currently stands at £23.7 billion and is 
predicted to rise to £39.8 billion by 2035 (Hex et al., 2012). These trends are mirrored 
globally and pose a serious threat to population health and economy.  
Alarmingly, T2D is something that in many cases can be averted with careful lifestyle 
choices such as a well-balanced diet, regular physical activity and maintaining a 
healthy body weight. The World Health Organisation (WHO) targets for 2025 are ‘halt 
the rise in diabetes and obesity’ and reduce the ‘prevalence of insufficient physical 
activity’ (WHO, 2014). This is proving to be a major public health challenge as despite 
global recommendations, physical inactivity is rising in modern society and is 
recognised ahead of obesity as the fourth leading risk factor for global mortality, 
following smoking, hypertension and hyperglycaemia (WHO, 2010). The mechanisms 
by which physical inactivity causes metabolic complications has important 
implications for understanding the development of associated diseases. Innovative 
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strategies are needed to reduce the closely linked epidemics of physical inactivity, 
obesity and T2D. 
Literature review 
This literature review will begin by describing whole body integrative physiology and 
inter-organ cross-talk. Obesity as a public health issue is then outlined, along with its 
associated chronic disease outcomes. The characterising features of metabolic 
syndrome (MetS) are reported and the idea of a ‘healthy’ type of obesity will be 
discussed. The concept of body fat distribution as opposed to total body fat will be 
detailed, as well as discussion of the role fat distribution plays in the development of 
insulin resistance (IR), non-alcoholic fatty liver disease (NAFLD) and ultimately T2D. 
The link between cardiorespiratory fitness (CRF) and mortality is examined, and risk 
factors for T2D are identified with a specific focus on habitual physical activity (PA) 
and sedentary behaviour. The review concludes with suggested research priorities for 
understanding the consequences of physical inactivity and based on these, the aims 
and objectives of the thesis are stated.  
1.1 Metabolic regulation  
The coordinated regulation of metabolic fuel selection is crucial to energy 
homeostasis. This section will discuss the liver, skeletal muscle and adipose tissue as 
major metabolic organs with a focus on how inter-organ cross-talk between these 
tissues mediates whole body metabolism. The physiology of metabolic regulation will 
be outlined first as understanding this is central to the appreciation of the 
pathophysiology associated with metabolic disease. The theory discussed is 
underpinned by textbooks (Frayn, 2010, Baynes and Dominiczak, 2014) and detail of 
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how these process are altered with in metabolic disease is taken from specific studies 
and cited throughout.  
1.1.1 Post-absorptive metabolism 
In the post-absorptive state (Figure 1.1A), the liver plays a primary role in maintaining 
plasma glucose concentration. Glucose enters the blood from the breakdown of liver 
glycogen and hepatic gluconeogenesis. The stimulus for this is a decreased 
insulin/glucagon ratio. A large proportion of this glucose is completely oxidised by the 
brain, the remaining is used by red blood cells and other glycolytic tissues whereby 
carbon is returned to the liver as lactate to be reused in gluconeogenesis. In the absence 
of nutrient intake, circulating insulin from the pancreas is low therefore skeletal muscle 
uptake of glucose is low but liberation of fatty acids (lipolysis) from adipose tissue is 
high. Plasma glucose and insulin concentrations are at their lowest (of a 24 hour cycle) 
whereas non-esterified fatty acids are at their highest, all are somewhat stable. Non-
esterified fatty acids are the preferred fuel for muscle. Fatty acids are also oxidised in 
the liver for gluconeogenesis and is accompanied by ketone body formation. Although 
not a major fuel, ketone bodies are oxidised by other tissues including the brain, 
skeletal muscle and adipose tissue. Furthermore, protein is broken down within 
skeletal muscle from muscle glycogen breakdown and a small amount of glucose 
uptake. Amino acids are oxidised, transferred to pyruvate to form alanine and taken up 
by the liver for gluconeogenesis.  
1.1.2 Post-prandial metabolism  
After the ingestion of a meal (Figure 1.1B), nutrients present at the portal vein and 
then general circulation within 15-30 minutes. The concentration of plasma glucose 
rises and the pancreas responds by insulin secretion. Plasma insulin concentration rises 
and glucagon decreases. These hormones in circulation have a direct suppressive effect 
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on lipolysis in adipose tissue. Non-esterified fatty acids are reduced and no longer 
oxidised by skeletal muscle and glucose uptake is increased. In turn, glycogen 
synthesis is stimulated, glycolysis increases, the output of lactate and pyruvate 
increases, and glucose oxidation increases. In the liver, glycogen metabolism switches 
from breakdown to synthesis.  Some amino acids are taken up by the liver although 
mostly branched-chain amino acids enter skeletal muscle; these are used in the muscle 
as an oxidative fuel but also for protein synthesis. Hepatic gluconeogenesis is 
maintained through lactate which leads to glucose 6-phosphate and directed into 
glycogen synthesis as opposed to glucose release.  
Overall, the ingestion of a meal causes a suppression of fatty acid release and promotes 
glucose utilisation, particularly to storage as glycogen. Muscle insulin action increases 
skeletal muscle glucose uptake, and adipose insulin action decreases hepatic fatty acid 
delivery and re-esterification of hepatic fatty acids into triglycerides. Direct hepatic 
insulin action will activate de novo lipogenesis (DNL) and conversion of excess 
carbohydrate substrate into triglyceride and will promote export of hepatic triglyceride 
to adipose tissue as very low density lipoprotein (VLDL). Towards the end of the post-
prandial period, triglycerides are transported to adipose tissue as chylomicrons where 
lipoprotein  lipase (LPL) activity has been increased by greater circulating insulin and 
esterification and storage of  fatty acids is promoted. After 3-5 hours, glucose and 
insulin concentrations decline which in turn promotes lipolysis and plasma non-
esterified fatty acids begin to rise.  
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Figure 1.1 Schematic of A) post-absorptive metabolism and B) post-prandial metabolism. FFA, free fatty acids TG 
triglyceride.  
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1.1.3 Excess calorie consumption  
In the context of obesity, it is important to note how subsequent meals (either in 
calorific excess or timed too closely) may promote energy storage. The insulin-
stimulated process can become ‘primed’ by the previous bolus. Therefore, non-
esterified fatty acids stay low, skeletal muscle and liver glycogen synthesis remains 
and storage of triglyceride in adipose tissue is almost continual. Over time, this will 
induce metabolic harm, the pathophysiology of this is discussed in detail later.  
1.2 Obesity  
Obesity can be defined as excessive adipose tissue, commonly known as body fat. 
Body mass index (BMI) is currently the most widely used method to classify weight 
and associated risk of co-morbidities (Table 1.1); calculated as body mass (kg) / height 
squared (m2). Obesity is defined as ≥30 kg/m2; in 2014, WHO estimated a 39% (1.9 
billion adults) global prevalence of being overweight, of which 13% (600 million 
adults) were obese. In England, obesity prevalence increased from 15% in 1993 to 
27% in 2015 (Health Survey for England, 2015). The prevalence of morbid obesity 
(≥40 kg/m2) has more than tripled since 1993, and reached 2% of men and 4% of 
women in 2015.  
The increasing prevalence of obesity is a major public health threat. Robust evidence 
has associated a higher BMI with a greater risk of premature all-cause mortality in 
1.46 million white adults (Berrington de Gonzalez et al., 2010) and across four 
continents (Global et al., 2016). Obesity is also strongly linked with the incidence of 
numerous conditions including hypertension, dyslipidaemia, IR, MetS, non-alcoholic 
fatty liver disease (NAFLD), T2D, cardiovascular disease (CVD), stroke, and some 
cancers (Prospective Studies, 2009). In 2015/16, there were 525,000 NHS hospital 
admissions whereby obesity was a factor. The projected future cost of treating obesity 
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and obesity-related disease is staggering. It is estimated to increase by £1.9–2 
billion/year in the UK and $48–66 billion/year in the USA by 2030 (Wang et al., 2011). 
Understanding the pathophysiology of obesity-related disease is paramount to reduce 
this economic burden.  
Table 1.1 World Health Organisation (WHO) classification of body mass index (BMI) 
and risk of co-morbidities. 
Classification BMI (kg/m2) Risk of co-morbidities 
Underweight <18.5 Risks associated with being underweight 
Normal weight 18.5 – 24.9 Average risk 
Overweight ≥25 Increased risk 
Pre-obese 25 – 29.9 Mild 
Obese class I 30 – 34.9 Moderate 
Obese class II 35 – 39.9 Moderate to severe 
Obese class III ≥40 Severe 
 
 
 
9 
 
1.2.1 Metabolic abnormalities in obesity 
Dysregulated metabolism, i.e. inefficiencies in the balancing and use of energy within 
the body, is thought to be the primary pathway of obesity-related disease (Frayn, 
2010). Obesity arises when energy intake exceeds energy expenditure for a prolonged 
period of time and, resultantly, excess energy is stored in the form of adipose tissue. 
Excessive amounts of adipose tissue can lead to a series of metabolic abnormalities 
including impaired circulation of blood throughout the body as indicated by elevated 
blood pressure (hypertension), impaired use of lipids as indicated by unbalanced levels 
of cholesterol and triglycerides in the blood (dyslipidaemia) and impaired use of 
glucose by body tissues as indicated by abnormally high levels of glucose in the blood 
(hyperglycemia). Gender and ethnic specific criteria has been developed to stratify the 
risk of these metabolic abnormalities along with central (i.e. abdominal) adiposity. 
These risk factors, which are closely linked and often appear together, can form a 
condition known as ‘metabolic syndrome’. 
1.3 Metabolic syndrome (MetS) 
MetS is not a disease per se, but is a term that highlights a grouping of traits that 
increase risk of disease, approximately 3-fold for CVD and 5-fold or more for T2D 
(Stern et al., 2004). There are multiple definitions of MetS; three globally recognised 
criteria are defined (Table 1.2). The International Diabetes Federation (IDF) definition 
(Alberti et al., 2009), estimates around 20-25% of the world’s adult population have 
MetS. The prevalence of MetS increases markedly with obesity (Katzmarzyk et al., 
2005), whereby central adiposity is thought to play a key role and may precede the 
appearance of associated cardiometabolic abnormalities and chronic diseases. The 
presence of hypertension, dyslipidaemia, increased central adiposity (waist-hip ratio 
or waist circumference) and hyperglycemia in some capacity is agreed between 
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definitions, as are gender differences. The National Cholesterol Education Program 
Adult Treatment Panel (NCEP / ATP III) (Stone et al., 2005) and IDF both consider 
prescription medicine as a surrogate risk factor for hypertension and dyslipidaemia. 
Additionally, IDF propose country (ethnic origin) specific waist circumference cut-
offs in order to account for population differences. Identifying individuals with MetS 
has potential importance within a health care setting where chronic diseases are often 
clinically ‘silent’ for a long time (O'Neill and O'Driscoll, 2015).  
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Table 1.2 World Health Organization (WHO), National Cholesterol Education Program Adult Treatment Panel (NCEP / ATP III) and International 
Diabetes Federation (IDF) definitions of metabolic syndrome (MetS). 
 WHO (1998) NCEP/ ATP III (2005) IDF (2009) 
Criteria IGT, IFG, T2D plus two 
of the following: 
Any three of the 
following: 
Three out of the following: 
Waist circumference (WC) 
Men: WHR >90; 
Women: WHR >0.85 
and/or BMI >30 kg/m2 
Men: WC ≥102 cm; 
Women: WC ≥88 cm 
Population country specific 
WC* 
Blood pressure 
≥140/90 mmHg 
≥130/85 mmHg 
or medicated 
≥130/85 mmHg 
or medicated 
Glucose  
IGT, IFG or T2D ≥5.6 mmol/l ≥5.6 mmol/l 
Triglycerides 
≥1.7 mmol/l 
≥1.7 mmol/l 
or medicated 
≥1.7 mmol/l 
or medicated 
High density lipoprotein Men: <1.0 mmol/l 
Women: <1.3 mmol/l 
Men: <1.0 mmol/l 
Women: <1.3 mmol/l 
or medicated 
Men: <1.0 mmol/l 
Women: <1.3 mmol/l 
or medicated 
*If BMI is >30kg/m², central obesity can be assumed and waist circumference does not need to be measured; see IDF criteria for population specific 
values.  IGT, impaired glucose tolerance; IFG, impaired fasting glucose; T2D, type 2 diabetes; WHR, waist-hip ratio; BMI, body mass index
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1.3.1 Metabolically healthy obese and metabolically unhealthy non-obese 
Historically, BMI has been widely used to stratify obesity status. Herein, metabolically 
unhealthy refers to the presence of metabolic syndrome (MetS+) and the term 
metabolically healthy refers to the absence of metabolic syndrome (MetS-). More 
recently, there is a growing recognition that not all obese individuals are unhealthy, 
termed metabolically healthy obese (MHO) and likewise, not all non-obese individuals 
are healthy, termed metabolically unhealthy non-obese (MUNO). Whilst this research 
is somewhat equivocal, the evidence to support these phenotypes has been recently 
reviewed (Phillips, 2017, Stefan et al., 2017). Many authors believe that cross-
sectional observations are a transient phase; it has been questioned whether these 
phenotypes really exist and if so the clinical significance of these. These 
inconsistencies may be due a lack of a universal definition of MetS and thus a 
considerable variation in prevalence reports.  
In a 20 year follow up study, it was found that one-half of MHO had made an adverse 
transition to metabolically unhealthy obese (MUO) and were also more likely to make 
this transition than MUNO (Bell et al., 2015a). Irrespective of the research disparity, 
these individuals are prevalent (estimated between 2-28% in Europe) within society 
and constitute a unique subset of characteristics. MHO display preserved insulin 
sensitivity, normal blood pressure, healthy lipid profiles and favourable fat distribution 
(Phillips, 2017). Contrary, MUNO display insulin resistance (IR), hypertension, 
dyslipidaemia as well as adipose tissue dysfunction and a body composition whereby 
the anatomical site of fat storage appears to be more important than total amount of 
body fat (Stefan et al., 2017). Body fat distribution is thought to be a distinguishing 
feature of metabolic status. It could be argued that independent of obesity, improving 
metabolic status is important to attenuate the development of cardiometabolic risk.  
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1.4 Body fat distribution  
An increase in BMI, as seen with obesity, commonly represents an accumulation of 
fat. However, excessive total body fat content does not always lead to cardiometabolic 
disruption and a vast amount of evidence has revealed that body fat distribution more 
accurately predicts risk (Tchernof and Després, 2013). The presence of fat stores 
within intra-abdominal anatomical structures, termed visceral adipose tissue (VAT), 
has emerged as one of the most prevalent manifestations of MetS and represents an 
essential feature of the obesity epidemic (Després and Lemieux, 2006). VAT is 
considered as part of a complex phenotype including adipose tissue storage 
dysfunction and ectopic triglyceride accumulation in several sites including skeletal 
muscle (intramyocellular lipid, IMCL), liver and pancreas (Després, 2011).  
A wealth of evidence has associated a greater waist-hip ratio with increased VAT and 
liver fat; strongly linking these and cardiometabolic disease (Després and Lemieux, 
2006, Fabbrini et al., 2009). The presence of fat stores at the periphery, termed 
subcutaneous adipose tissue (SAT), is considered less important in the 
pathophysiology of chronic disease development (Ibrahim, 2010) and increased lower-
body SAT is thought to be protective (Karpe and Pinnick, 2015). A metabolically 
healthy individual has more SAT, less VAT, and lower ectopic fat deposition in 
skeletal muscle and the liver than a metabolically at-risk individual (Figure 1.2) 
(Stefan et al., 2013). Obesity is commonly associated with IR (Petersen and Shulman 
2006; Gill et al. 2005), however some non-obese individuals have IR which is 
associated with their ectopic fat stores (Jensen et al. 1989; Lim and Meigs 2014).  
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1.5 Insulin resistance (IR) 
IR is a pathological condition in which high insulin concentrations fail to produce a 
normal response in peripheral target tissues (Benito, 2011). It is a common feature of 
obesity, MetS, NAFLD and T2D. Skeletal muscle IR disrupts insulin-mediated glucose 
uptake and decreases glycogen synthesis. Hepatic (liver) IR impairs the ability of 
insulin to suppress glucose production. Adipose tissue IR attenuates the anti-lipolytic 
Figure 1.2 A comparison of body fat distribution in a metabolically healthy and 
metabolically at-risk individual (Stefan et al., 2013). 
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effect of insulin which leads to elevated free fatty acid. This metabolic setting increases 
the demand for pancreatic β-cells to synthesise and secrete more insulin. Eventually, 
the inability of pancreatic β-cells to produce enough insulin leads to elevated fasting 
glucose, glucose intolerance, and ultimately T2D (Petersen and Shulman 2006; Gill et 
al. 2005). Ectopic lipid accumulation in skeletal muscle and liver triggers pathways 
that impairs insulin signalling at the key insulin-responsive tissues (liver, skeletal 
muscle, and adipose tissue) (Samuel and Shulman, 2016).  
1.6 Liver fat  
The role of skeletal muscle IR in the pathogenesis of liver fat and hepatic insulin 
resistance has been evidenced (Petersen et al., 2007). A defect in muscle glycogen 
synthesis by decreased insulin-stimulated glucose transport activity due to selective 
ectopic IMCL accumulation and inhibition of muscle insulin signalling occurs. With 
post-prandial hyperinsulinemia and hyperglycemia excess energy is directed to the 
liver which stimulates hepatic DNL. Hepatic triglyceride synthesis is increased 
resulting in increased VLDL production, hypertriglyceridemia, and reductions in 
plasma HDL. As IR progresses towards T2D (Figure 1.3), the accumulation of liver 
fat (hepatic steatosis) increases and insulin signalling in the liver, skeletal muscle, and 
adipose tissue decreases. Rates of adipose tissue lipolysis are increased, resulting in 
increased fatty acid delivery to liver, which results in increased hepatic esterification 
of fatty acids to triglyceride. In contrast, hepatic DNL, which is dependent on hepatic 
insulin signalling, is reduced. The accumulation of liver fat in the development of T2D 
is pivotal (Taylor, 2013). To note, VAT does not appear to be pathophysiologically 
related (Fabbrini et al., 2009). 
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Figure 1.3 Schematic of A) normal insulin action, B) prediabetic insulin action and 
C) insulin action in type 2 diabetes (Samuel and Shulman, 2016). 
17 
 
1.7 Metabolic effects of exercise  
It is well established that exercise improves insulin sensitivity (Roberts et al., 2013, 
Bird and Hawley, 2016). It does this primarily by contraction-induced skeletal muscle 
glucose uptake (Richter and Hargreaves, 2013). In addition to its mechanical role 
(locomotion), skeletal muscle accounts for up to 75% of blood glucose uptake in the 
post-prandial state. During exercise the increased contraction-stimulated glucose 
uptake is linked to increases in AMP-activated protein kinase (AMPK), which results 
in the glucose transporter type 4 (GLUT4) translocation and ultimately glucose uptake 
(Cartee, 2015, Sakamoto and Holman, 2008). Exercise training as been shown to 
improve GLUT4 concentrations in individuals with MetS and T2D (Stuart et al., 
2013). Improvements appear to be tissue specific, in skeletal muscle but not hepatic 
IR, nor insulin-stimulated glucose uptake in adipose tissue (Malin et al., 2013, 
Reichkendler et al., 2013).  
Exercise can also have a profound effect on the distribution and metabolic fate of an 
ingested meal. As such, reversal of skeletal muscle IR, with exercise, has been shown 
to reduce post-prandial hepatic DNL. In young, lean, but insulin resistant individuals, 
a single bout of exercise diverted ingested carbohydrate away from the liver and into 
the muscle, thereby reducing hepatic DNL and hepatic triglyceride synthesis (Rabol et 
al., 2011). Further, 6 weeks of exercise training has been shown to increase glucose 
transport-phosphorylation and muscle glycogen synthesis in insulin resistant subjects 
(Perseghin et al., 1996).  
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1.8 Mechanisms of habitual activity versus physical inactivity 
A consequence of physical inactivity is a lack of AMPK activation and glucose uptake 
from skeletal muscle (Figure 1.4) this triggers insulin resistance and provides a 
substrate for DNL in adipose tissue and liver. Consequently, there is expansion of 
adipose tissue mass, an increase in FFA flux and serum FFA, intra-hepatic lipid 
accumulation and increased lipid exports as VLDL triglyceride particles and serum 
TG with systemic insulin resistance. On the contrary, being habitually active promotes 
AMPK activation and uptake of glucose in skeletal muscle; insulin sensitivity is 
therefore preserved and less glucose is diverted to metabolically unfavourable depots.  
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Figure 1.4 Schematic of proposed mechanisms of habitual activity versus physical inactivity. FFA, free fatty acids; VLDL, very low 
density lipoproteins; TG, triglycerides; AMPK, AMP-activated protein kinase. 
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1.9 Adipose tissue expandability hypothesis  
It is important to recognise the ‘adipose tissue expandability hypothesis’ to explain the 
accumulation of ectopic fat. It is suggested that to accommodate increased lipid supply 
in a state of positive energy balance, SAT must undergo expansion to avoid deposition 
of lipid in non-adipocyte cells (Rutkowski et al., 2015). The expansion of SAT can 
occur by either hypertrophy or hyperplasia but once maximal SAT expansion is 
reached, widespread organ specific ectopic fat deposition (steatosis) occurs (e.g. liver, 
pancreas) with secondary functional consequences (lipotoxicity) (e.g. hepatic insulin 
resistance, impaired β-cell function) (Gray and Vidal-Puig, 2007).  
1.10 Personal fat threshold  
A ‘personal fat threshold’ (PFT) has been proposed (Taylor and Holman, 2015) which 
may explain the large inter-variation in ones SAT expansion capacity. The PFT is a 
concept of explaining the onset of T2D in non-obese individuals. All individuals have 
a PFT, i.e. a different weight/BMI at which SAT expansion has reached its capacity. 
Once further weight gain occurs, metabolic decompensation ensues. Metabolically 
unhealthy non-obese may have a low PFT whereas metabolically healthy obese may 
have a high PFT (Figure 1.5).  
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Figure 1.5 The ‘personal fat threshold’ adapted to demonstrate healthy and unhealthy 
metabolic phenotypes (Taylor and Holman, 2015). 
 
1.11 Non-alcoholic fatty liver disease (NAFLD) 
The liver has an integral role in the regulation of glucose and lipid regulation. 
Consequently, dysregulated metabolism within the liver has significant implications 
for metabolic disease. Closely linked with the development of T2D, it is recognised 
that hepatic steatosis (the initial stage of NAFLD) should be targeted early to prevent 
its progression and associated complications. NAFLD represents a spectrum of liver 
disease ranging from isolated fatty liver to progressive non-alcoholic steatohepatitis 
(NASH), hepatic fibrosis, and cirrhosis. If cirrhosis develops ~33% of patients will 
develop morbid conditions or die a liver related death (Hui et al., 2003). Hepatic fat 
accumulation ≥5% in the absence of excess alcohol consumption (>20 g/day) is 
classified as NAFLD (Browning et al., 2004). It is reported that 80% of T2D patients 
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have NAFLD (Targher et al., 2007). NAFLD has been described as a major factor in 
the outcome and contribution to T2D and is considered the hepatic manifestation of 
MetS closely linked with obesity and IR (Rector et al., 2008). NAFLD is now the most 
common liver disease in both adults and children, and hepatic insulin resistance is 
strongly linked to NAFLD, which is a major factor responsible for the transition from 
normoglycemia to impaired glucose tolerance and T2D.   
1.12 Type 2 diabetes (T2D) 
The development of T2D is strongly linked with the aforementioned: obesity, MetS, 
IR and liver fat (Zaccardi et al., 2016); however non-obese individuals can also 
develop the disease (Vaag and Lund, 2007). T2D is a complex metabolic disorder, 
characterised by progressive defects in insulin secretion and action in which 
hyperglycemia develops (Inzucchi, 2012). The earliest indicator of T2D risk is skeletal 
muscle IR (Petersen et al., 2007) however this solely does not cause hyperglycemia 
and does not dictate pathogenesis (Taylor, 2017). T2D occurs in the presence of 
chronic positive energy balance in which the ‘twin cycle hypothesis’ (Figure 1.6) 
causes a permissive environment for the development of the disease (Taylor, 2008). 
This hypothesis unifies the vicious cycles of liver glucose production (‘liver cycle’) 
and β-cell function (‘pancreas cycle’). β-cell dysfunction is the final and determining 
factor of T2D onset. 
In positive energy balance, excess carbohydrate must undergo DNL, promoting the 
accretion of liver fat (Petersen et al., 2007). Pre-existing peripheral IR causes 
hyperinsulinemia which can exacerbate liver fat due to the additional requirement of 
insulin for DNL. The accretion of liver fat is associated with defects in suppression of 
glucose production (Seppala-Lindroos et al., 2002). The liver becomes less sensitive 
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to insulin, plasma glucose rises and basal insulin secretion is greater. With 
accumulation of liver fat and elevated plasma glucose, overproduction of VLDL 
triglyceride occurs (Adiels et al., 2006) which increases triglyceride delivery to all 
tissues including the pancreatic islets. Excess triglyceride in the islets will impair the 
acute insulin secretion in response to ingested food and cause post-prandial 
hyperglycemia. Eventually the inhibitory effects of triglyceride and glucose on the 
islets reach a level that T2D prevails. 
Post-absorptive plasma glucose concentration is maintained by the liver between a 
narrow range in healthy individuals whereby the basal rate of glucose uptake is 
matched by the rate of endogenous glucose production. In T2D, hepatic insulin 
resistance causes poor control of glucose production which is believed to exacerbate 
hyperglycemia (DeFronzo et al., 1992).  The post-prandial regulation of glucose 
depends on the suppression of endogenous glucose production and increased glucose 
uptake with stimulation of glucose oxidation. Hyperglycemia following ingestion of a 
meal is a hallmark feature of T2D (DeFronzo et al., 1982). In comparison to healthy 
controls, T2D patients are unable to maintain suppression of glucose production after 
a mixed meal (Singhal et al., 2002).  
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Figure 1.6 The ‘twin cycle hypothesis’ of the etiology of type 2 diabetes (T2D) 
(Taylor, 2013). 
 
1.12.1 Multiple pathophysiological failures that contribute to hyperglycaemia 
β-cell dysfunction is the final denominator in T2D. The ‘egregious eleven’ is a 
classiﬁcation schema outlining the pathways known to mediate hyperglycemia 
(Schwartz et al., 2016). It is important to note that whilst this thesis focuses towards 
insulin resistance (liver, skeletal muscle, adipose tissue) there are an array of other 
mechanisms associated with the development of T2D. Other mechanisms include the 
brain, colon/biome, and immune dysregulation/inﬂammation and other β-cell 
dysfunctions through downstream effects, reduced insulin, decreased incretin effect, 
α-cell defect, stomach/small intestine via reduced amylin, and kidney (Figure 1.7).  
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Figure 1.7 Multiple pathophysiological failures contribute to hyperglycaemia. 
 
1.12.2 Familial predisposition for T2D 
First-degree relatives (FDR) of individuals diagnosed with T2D are at a 3-fold 
increased risk of developing the disease themselves (Meigs et al., 2000). These 
individuals display IR which is compensated by β-cell hyperinsulinemia, reduced basal 
energy consumption and cardiometabolic abnormalities including lipid disorders and 
high blood pressure long before the disease onset (Groop et al., 1997). In these 
individuals, IR is the best predictor of the development of diabetes and plays an 
important part in its pathogenesis (Perseghin et al., 1996). The genetic predisposition 
for T2D is irrefutable (Almgren et al., 2011) but non-genetic factors also play a 
prominent role in whether an individual progresses to overt T2D (Poulsen et al., 1999). 
Non-genetic factors include pre/postnatal environment, energy intake and energy 
expenditure, the review herein focusses on the later.  
 
26 
 
1.13 Energy expenditure 
Obesity-related disease and T2D occurs in a state of positive energy balance. Energy 
balance can be altered either by energy intake (nutrient consumption) and energy 
expenditure. Energy expenditure can be influenced in a number of ways. Basal 
metabolic rate (BMR), which is the amount of energy needed to keep the body 
functioning at rest, is the largest component of energy expenditure. BMR is predicted 
by intrinsic factors such as body composition, age, sex, and ethnicity (Weyer et al., 
1999). Dietary induced thermogenesis (DIT), is the amount of energy needed to 
process food for use and storage. DIT is influenced by the energy intake, macronutrient 
composition, and eating pattern of the meal (Quatela et al., 2016) and constitutes to 5 
to 15 % of daily energy expenditure (Westerterp, 2004). Activity thermogenesis, which 
can vary from about 15% for inactive to 50% for active individuals (Donahoo et al., 
2004), is the amount of energy expended through PA. This component can be sub-
divided into exercise activity thermogenesis and non-exercise activity thermogenesis 
(NEAT). NEAT incorporates general, everyday activity.  
1.14 Cardiorespiratory fitness 
The independent protective effect of high CRF against all-cause mortality has been 
long established (Blair et al., 1989, Ekelund et al., 1988). Obesity (discussed above) 
and low CRF are considered to be central mechanisms in the development of T2D. 
CRF is an objective marker of PA level (Garber et al., 2011). The preventive role of 
PA in the development of T2D (Lee et al., 2009) can be explained through epigenetic 
modification that may improve that may improve glucose homeostasis (Barres et al., 
2012, Lindholm et al., 2014). A higher CRF at baseline is associated with lower risk 
of T2D during follow-up (Aune et al., 2015) and maintaining a high CRF level over 
time is beneficial (Momma et al., 2017). Of note, is the ‘fitness versus fatness’ debate. 
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High CRF has a been demonstrated to have a stronger protective effect on diabetes in 
obese than in normal weight men (Holtermann et al., 2017) and a ‘fit-fat index’ has 
been proposed as a better indication of incident risk when compared to fitness or 
fatness alone (Sloan et al., 2016). Recent studies have suggested that recommendations 
to improve CRF should move beyond weight change (i.e. emphasise PA) (Dollar et 
al., 2017). CRF was positively associated with increased β-cell function independent 
of fatness in individuals with MetS (Ramos et al., 2017). No weight loss but increased 
CRF and increased cardiovascular function has also been shown in patient groups 
(Sprung et al., 2013). There is no doubt that high CRF has therapeutic effects in the 
prevention the cardiometabolic complications related to T2D; and the growing body 
of evidence suggests this can be independent of body weight (Barry et al., 2014, 
Pedersen, 2007, Fogelholm, 2010).  
1.15 Physical activity and health 
The value of PA for health is not disputed. Research conducted by Jeremy Morris and 
colleagues pioneered this field (Morris et al., 1953). Their seminal study conducted in 
the 1950’s compared the risk of coronary heart disease (CHD) in bus drivers who were 
physically inactive during their working day (i.e. driving) versus bus conductors who 
were physically active (i.e. walking up and down the bus). The investigators concluded 
that employees in positions that required high physical activity, i.e. the bus conductors, 
had lower rates of CHD. Since then, the relationship between physical inactivity and 
major non-communicable diseases has been well evidenced (Lee et al., 2012). Despite 
robust evidence and evolving public health messages, physical inactivity continues to 
emerge as a major, and indeed growing, worldwide health threat. It is estimated in the 
UK that 50% of women, and a third of men are damaging their health through physical 
inactivity. This not only has consequences for health, it also places a substantial 
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financial strain on health services. In 2006/07, the estimated cost of physical inactivity 
in the NHS was £0.9 billion (Scarborough et al., 2011).  
1.16 Definitions of exercise, physical (in)activity and sedentary behaviour  
Bodily movement covers a broad spectrum, from sleep, sitting down, standing up, low 
level physical activity to moderate and vigorous physical activity. Figure 1.8 
contextualises the key terms relating to activity that will be used throughout this thesis. 
There have been many studies outlining the health benefits of regular ‘exercise’, 
focusing on high-energy expenditure (moderate-vigorous activity) and there is a well-
established field of ‘exercise physiology’. Exercise is deliberate movement intended 
to improve or maintain physical fitness, for example playing sports or going to the 
gymnasium. ‘Physical activity’ (PA), on the other hand, is any bodily movement that 
requires more energy than resting, for example, getting ready for work, carrying 
groceries or walking to the bus stop. Performing less than 30 minutes of physical 
activity a week is classified as inactive. More recently, there has been emerging data 
on ‘inactivity physiology’ with the recognition that the whole body, tissue-specific and 
cellular consequences of inactivity do not necessarily represent opposites to those that 
occur with exercise or high levels of physical activity. Studies of physical inactivity, 
focus on the physiological impact of a lack of human movement.  
‘Sedentary behaviour’, (loosely defined as lying, reclining or sitting) is classified as 
≤1.5 metabolic equivalents (METS) is a broad term were specific investigations 
regarding daily sitting, television viewing and screen based time have been carried out. 
It is important to note that sedentary behaviour is not simply a lack of physical activity, 
an individual can be physically active as well as sedentary especially in modern society 
where changes in technology, occupation, transportation and dietary availability have 
created a permissive environment for reduced PA and/or sedentary behaviour. Daily 
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sedentary time appears to exert deleterious effects on metabolism even in individuals 
who meet current intensity-based physical activity guidelines (Hamilton et al., 2014). 
The importance of considering the entire waking day, and active and inactive 
behaviours within it have been noted (Hamilton et al., 2007). This includes 
understanding how low intensity physical activity can replace large amounts of 
sedentary time.  
 
 
Figure 1.8 A spectrum of bodily movement to contextualise key terms; ‘sedentary’ 
behaviour at low level energy expenditure, ‘physical activity’ being intermediate, and 
‘exercise’ being moderate and vigorous activity with higher energy expenditure.
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1.17 Why move away from exercise research? 
Regular exercise has beneficial effects on obesity, MetS, T2D, NAFLD, CVD, some 
cancers and overall mortality. Historically, public health activity guidelines have 
emphasised the importance of exercise, with 150 minutes of moderate-vigorous 
physical activity (MVPA) recommended per week. However, statistics reveal that a 
quarter of the people in the UK are failing to achieve a minimum of 30 minutes of 
activity per week (PHE, 2014). While the benefits of exercise are well established, low 
physical activity is an independent risk factor for ill-health often not considered. 
Relative to the substantial body of work examining the acute and chronic effects of 
exercise, relatively little is known about physical inactivity. Western society has 
changed drastically, there is evidence for a reduction in occupational energy 
expenditure as well as greater time spent sitting daily (Church et al., 2011, Althoff et 
al., 2017). The development of alternative PA strategies are challenging given that 
sedentary time has become a monumental part of life in the modern world. The 
interrelated epidemics of obesity, T2D and physical inactivity are projected to continue 
growing, thus, effective PA guidelines that are achievable and attainable at a 
population level are vital. A simple behaviour approach could be key.  
1.18 Habitual physical activity 
Shifting to the emphasis of PA rather than exercise, per se, will target the whole 
waking day as opposed to 30 minutes, 5 times a week. Assessment of habitual PA 
indicates strong links between physical inactivity and obesity in cross-sectional 
(Myers et al., 2016) and follow up studies (Shook et al., 2015). Importantly, even 
subtle changes to habitual PA can have a positive effect on health. A recent prospective 
cohort study evidenced an association between active commuting and incident 
cardiovascular disease, cancer, and mortality (Celis-Morales et al., 2017) and stair 
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climbing which requires no specialist equipment can improve CRF (Allison et al., 
2017). 
1.19 Sedentary behaviour  
Sedentary time has been associated with negative health outcomes, independent of PA 
(Biswas et al., 2015) and MVPA (Henson et al., 2013). Further it has been associated 
with liver and visceral fat in individuals at a high risk of T2D (Henson et al., 2015) 
and normal weight healthy adults (Smith et al., 2014). Replacing sedentary time with 
low intensity PA can improve lipid and glucose metabolism for the prevention of T2D 
(Hamilton et al., 2014). Breaking up prolonged periods of sitting (e.g. standing or 
walking) has been shown to be beneficial in glucose metabolism in women at high risk 
of T2D (Henson et al., 2016) and more recently upper limb activity had positive 
glycaemic effects despite maintaining a seated posture (McCarthy et al., 2017).  
1.20 Experimental models of physical inactivity  
There is an emerging interest in studies of reduced human movement; from which 
drastic research has been carried out investigating the effects of bed rest (Alibegovic 
et al., 2010), limb immobilisation (Abadi et al., 2009) and cessation of exercise in 
trained volunteers (King et al., 1988). Whilst these studies are informative, they 
represent extreme models of physical inactivity and translations to consequences in a 
free-living environment are somewhat limited. More recent investigators have 
employed a model of reduced ambulatory activity, a step-reduction protocol whereby 
individuals have been transitioned from high levels of physical activity (~10,000 
steps/day) to low levels of physical activity (~1,500 steps/day) for a period of 14 days. 
The consequences of this short-term reduced physical activity are somewhat striking, 
especially given the volunteers were young healthy males (Krogh-Madsen et al., 2010, 
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Olsen et al., 2008). Such changes have included reduced CRF, accumulation of central 
fat, loss of skeletal muscle mass and reductions in peripheral insulin sensitivity (Table 
1.3). One of the studies also induced overfeeding (Knudsen et al., 2012) and was the 
only investigation to re-assess their participants after resumption of normal activity; 
CRF and fasting blood measures returned back to normal but changes in body 
composition were not fully reversed. The effects of physical inactivity has also been 
investigated in older adults where a reduction in skeletal muscle mass was associated 
with anabolic resistance (Breen et al., 2013). None of these previous studies have 
objectively measured sedentary behaviour.  
1.21 Physical inactivity and T2D 
Physical inactivity contributes to a positive energy balance and as such obesity, which 
are key players in the development of IR known to exacerbate the progression of T2D. 
One plausible paradigm suggests that physical inactivity causes a reduction in skeletal 
muscle insulin sensitivity, contributing to a repartitioning of energy substrates into 
storage, increasing central fat accumulation and ectopic storage within the liver and 
other organs, causing further IR (Jornayvaz et al., 2010, Rabol et al., 2011, Rector and 
Thyfault, 2011, Petersen et al., 2007, DeFronzo and Tripathy, 2009). As peripheral IR 
progresses, continued ectopic fat accumulation within the liver and pancreas 
precipitates development of metabolic syndrome, a progressive decline in ß-cell 
function and ultimately T2D (Tan and Vidal-Puig, 2008).  An inactive lifestyle further 
increases the risk of developing T2D in FDR compared to those without (Hu et al., 
1999). Bed rest studies have compared FDR and healthy controls (Alibegovic et al., 
2009, Hojbjerre et al., 2011) but no previous studies have investigated the 
consequences of free-living short-term physical inactivity in those with a genetic 
susceptibility of developing T2D.
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Table 1.3 Summary of human studies inducing an ‘inactivity protocol’ as an experimental model of reduced physical activity. 
Reference Participant cohort Inactivity protocol Cardiorespiratory Body composition Metabolic 
(Olsen et 
al., 2008) 
Substudy 1 
Age 27.1  5.7 y 
BMI 22.9  4.0 
kg/m2 
Gender 8 males 
Baseline activity 
>3,500 steps/day; 
<2 hr exercise/week 
Screening period 
7 day 
Step count 
(pedometer) 
Dietary records 
21 day step-reduction 
Day 0: 6203 steps/day 
(95% CI, 5135 to 
7271) 
Day 7: 1394 steps/day 
(95% CI, 1261 to 
1528) 
 
Not measured Not measured 
3 hr oral glucose (75 
g) tolerance test 
↑ insulin AUC 
from 757 pmol/L/3h 
(95% CI, 488 to 
1026) 
at day 0 to 1352 
pmol/L/3h (95% CI, 
1025 to 1678) at day 
21 
(Olsen et 
al., 2008) 
Substudy 2 
 
Age 23.8  4.6 y 
BMI 22.1  2.1 
kg/m2 
Gender 10 males 
Baseline activity 
>3,500 steps/day; 
<2 hr exercise/week 
Screening period 
7 day 
Step count 
(pedometer) 
Dietary records 
 
14 day step-reduction 
Day 0: 10501 
steps/day (95% CI, 
8755 to 12247) 
Day 14: 1344 
steps/day (95% CI, 
1272 to 1416) 
 
Not measured 
MRI 
↑ 7% intra-abdominal 
fat mass from 693 
mL (95% 
CI, 485 to 902 mL) at 
day 0 to 740 mL 
(95% CI, 552 to 929 
mL) at day 14 
DXA 
↔ fat mass 
↓ 2 % total fat-free 
mass 
↓ BMI 
 
3 hr oral glucose (75 
g) tolerance test 
↑ insulin AUC 
from 599 pmol/L/3h 
(95% CI, 489 to 709) 
at day 0 to 
942 pmol/L/3h (95% 
CI, 443 to 1440) at 
day 14 
↑ C-peptide AUC 
8 hr oral fat (2 
ml/kg) tolerance test 
↑ insulin AUC 
↑ triglyceride AUC 
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(Krogh-
Madsen et 
al., 2010) 
 
Age 23.8  1.5 y 
BMI 22.1 0.7 kg/m2 
Gender 10 males 
Baseline activity 
>3,500 steps; 
<2 hr exercise/week, 
Screening period 
7 day 
Step count 
(pedometer) 
Physical activity 
(Actiheart) 
Dietary records 
 
14 day step-reduction 
Day 0: 10501 step/day 
(95% CI, 8755 to 
12247) 
Day 14: 1344 (95% CI, 
1272 to 1416) 
steps/day 
V̇O2 max (cycle 
ergometry) 
↓7.2% ml.min 
↓6.6% ml.min.kg 
 
 
 
 
 
 
 
 
DXA 
↓ 2.8% leg lean mass 
↓ 1.7% total body 
mass 
↔ arm lean mass 
↔ trunk lean mass 
 
Hyperinsulinaemic-
euglycaemic clamp 
↓ peripheral insulin 
sensitivity 
(17% reduction in 
glucose infusion rate, 
GIR) 
↔ endogenous 
hepatic glucose 
production 
 
(Knudsen et 
al., 2012) 
Age 24  3.3 y 
BMI 21.6  2.5 
kg/m2 
Gender 9 males 
Baseline activity 
>3,500 steps; 
<2 hr exercise/week, 
Screening period 
4 day 
Step count 
(pedometer) 
Physical activity 
(Actiheart) 
Dietary records 
 
14 day step-reduction 
Day 0: 10278 step/day 
(SE 715) 
Day 14: 1521 
steps/day (SE 131) 
plus overfeeding 
 
V̇O2 max (cycle 
ergometry) 
↓3.8% ml.min and  
↓3.4% ml.min.kg  
 
MRI  
↑ 49% visceral fat  
 
DXA 
↔ total fat-free mass 
↑ total body mass, 
BMI, whole body fat, 
android and gynoid 
fat 
 
 
Hyperinsulinaemic-
euglycaemic clamp 
↓ peripheral insulin 
sensitivity 
↔ endogenous 
hepatic glucose 
production 
3 hr oral glucose (75 
g) tolerance test 
↑ insulin AUC 
↔ glucose AUC 
↓ 26% Matsuda index 
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1.22 Aims and objectives  
From the representative literature discussed within this review, it is clear that physical 
inactivity and obesity can contribute to the development of IR and ultimately T2D. It 
is recognised that not all obese individuals are at risk of developing T2D, 
understanding the potential role of habitual PA in these individuals may reveal novel 
approaches to guidelines. Furthermore, accumulation of liver fat, which occurs only in 
a state of positive energy balance, is pivotal in the development of T2D; physical 
inactivity and sedentary behaviour may contribute significantly to this. The effects of 
short-term physical inactivity have been studied however the consequences in those 
with a genetic susceptibility (FDR) for T2D have not been investigated. This research 
has potential implications for the generation and implementation of PA 
recommendations.  
1. To explore whether differences in habitual PA and sedentary behaviour 
explains the metabolic health status of individuals that are obese and non-obese 
2. To use objective monitoring of PA and sedentary behaviour to investigate 
relationships between domains of physical activity and liver fat  
3. To determine the effects of short-term physical inactivity in first-degree 
relatives of patients with T2D compared with healthy controls. 
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Chapter 2.  
General methodology 
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This chapter outlines the general methods undertaken to meet the aims and objectives 
of this thesis. Specific methodology for each study can be found within the respective 
method sections for each data chapter. Unless explicitly noted, these procedures and 
analyses were conducted by myself (KBD). 
2.1 Participants  
All participants studied within this thesis were free from any disease. The cohort were 
from varying socio-economic backgrounds either living, working and/or studying in 
Merseyside and Greater Manchester (United Kingdom, UK). The demographics are 
somewhat representative of the adult UK population including males and females aged 
18-60 years, as well variable education, nationality, religion, and ethnicity.  
2.2 Recruitment  
Participants were recruited following their response to local adverts (METRO and 
ECHO newspapers and Radio Merseyside station) as well as internal adverts (poster, 
email, online intranet) within the University of Liverpool and University Hospital 
Aintree. ‘Word of mouth’ also generated a significant response. Patients with 
hyperlipidaemia and suspected fatty liver were prospectively recruited from specialist 
lipid and hepatology outpatient clinics at University Hospital Aintree. First-degree 
relatives of type 2 diabetes mellitus (T2D) were targeted via specific meetings and 
clinics including; Knowsley Community Diabetes Service, University Hospital 
Aintree Diabetes Centre, Diabetes UK group meetings and Help BEAT Diabetes 
campaign.  
2.3 Screening  
All participants were screened by questionnaire to ensure they were non-smokers and 
consumed <14 units of alcohol per week, females could not be pregnant. Individuals 
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who had any cardiovascular, respiratory, kidney, liver and/or endocrine diseases were 
excluded. Safety to undergo magnetic resonance (MR) scanning was determined by 
experienced personnel at Liverpool Magnetic Resonance Imaging Centre (LiMRIC). 
MR exclusion criteria included; cardiac pace-maker, metal implants or metallic 
cerebral aneurysm clips, non-removable metal jewellery, body weight >140 kg and 
those who experience claustrophobia. Physical Activity Readiness Questionnaire 
(PARQ) was used to assess suitability for maximal exercise testing, those with 
contraindications were excluded. In studies including dual-energy x-ray 
absorptiometry (DXA), a ‘justification of radiation exposure’ was conducted by Dr 
Cuthbertson.  DXA exclusion criteria included; body weight >200 kg, medical 
radiation exposure in last 7 days, non-removable metal jewellery and internal metal or 
plastic.   
2.4 Ethics and consent 
The studies included within this thesis conformed to the Declaration of Helsinki and 
were approved by the University of Liverpool Research Office, the Local Research 
Ethics Committee (LREC) at Liverpool Central and University Hospital Aintree 
(Research and Development). All participants were informed of the methods in writing 
and verbally before providing written informed consent.  
2.5 First-degree relative (FDR) of T2D 
Participants with a first-degree relative (FDR) of T2D are individuals with a parent, 
sibling or offspring medically diagnosed with the disease. This was verified verbally 
during consent.  
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2.6 Metabolic syndrome (MetS) 
In chapter 3 individuals are categorised as ‘healthy’ and ‘unhealthy’. Those who are 
unhealthy have 3 or more components of metabolic syndrome (MetS+), those who are 
healthy have two or less (MetS-) (Table 2.1).  
Table 2.1 Criteria for metabolic syndrome (MetS). 
 
Metabolic syndrome 
Three or more of the following: 
Waist circumference* Population specific 
Blood pressure ≥130/85 mmHg or medicated 
Fasting glucose ≥5.6 mmol/l 
Triglycerides ≥1.7 mmol/l or medicated 
High density lipoprotein; HDL M: <1.0 mmol/l, F: <1.3 mmol/l 
* If BMI is >30kg/m², central obesity can be assumed and waist circumference does 
not need to be measured; see IDF criteria for population specific values (Alberti et al., 
2009).  
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2.7 Overview of assessment measures  
Figure 2.1 displays an overview of assessment measures, dashed lines indicate 
measures not included in all studies; skeletal muscle (SkM) and subcutaneous adipose 
tissue (SAT) biopsies were optional. Following measures of anthropometry and 4 days 
of habitual assessment (which included physical activity monitoring and dietary 
record), participants attended two assessment visits. Assessment visit A took place at 
University Hospital Aintree including: fasting bloods, 2 hr oral glucose tolerance test 
(OGTT) and assessment of cardiorespiratory fitness (V̇O2). Assessment visit B took 
place at University of Liverpool campus including: vascular measures (carotid intima-
media thickness, cIMT; flow-mediated dilation, FMD), MR scanning (magnetic 
resonance imaging, MRI; magnetic resonance spectroscopy, MRS) and DXA. Specific 
details of each measure are outlined below. Participants were instructed to fast 
overnight for ≥8 hours, abstain from alcohol or caffeine for 24 hours and refrain from 
exercise for 48 hours prior to assessment visits.  All visits were standardised and took 
place in the morning to account for circadian variation.  
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Figure 2.1 Overview of assessment measures.  SkM, skeletal muscle; SAT, subcutaneous adipose tissue; OGTT, oral glucose tolerance 
test; V̇O2, cardiorespiratory assessment; cIMT, carotid intima-media thickness; FMD, flow-mediated dilation;  MRI, magnetic 
resonance imaging; MRS, magnetic resonance spectroscopy; DXA, dual-energy x-ray absorptiometry. Dashed lines indicate measures 
not included in all studies. 
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2.8 Anthropometric measurements 
Following consent, anthropometric measurements were taken to ensure participant 
suitability for MR and DXA scanning. Height and weight, were also required at this 
stage for the configuration of the physical activity monitor; of note, gender, date of 
birth and handiness were required, these details were collected during screening.  
Height was measured, whilst participants were standing upright (with their back and 
head straight so that their Frankfurt plane was horizontal), to the nearest 0.5cm using 
a stadiometer (Model 220, Seca, Germany). Tanita bio-impedance analysis was 
conducted on electronic digital scales (Model BC 420, Dolby Medical Stirling, UK); 
this provided total body mass, fat percentage, fat mass, fat free mass, muscle mass, 
total body water, basal metabolic rate, bone mass and visceral fat indicator. Body mass 
index (BMI; mass (kg) / height (m)2) was calculated from total body mass and height. 
Waist circumference measurements (at the umbilicus) and hip circumference 
measurements (at the greater trochanter) were taken in duplicate, waist to hip ratio 
(WHR; waist circumference (cm) / hip circumference (cm)) was calculated from this. 
After a period of 5 minutes rest, blood pressure (mmHg) and resting heart rate (bpm) 
were determined from an average of three measures using an automated monitor 
(Dinamap, G & E Medical, USA). 
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2.9 Physical activity monitoring  
Participants’ habitual physical activity was assessed using a SenseWear armband 
(Model MF-SW, BodyMedia, UK) (Figure 2.2). Instructions were given for the 
armband to be worn on their left arm at all times except when showering or bathing, 
inclusion criteria was >90% wear time. Monitoring was conducted on 4 consecutive 
days from midnight to midnight on, including one weekend day, in the days preceding 
an assessment visit. This protocol was employed based on previous literature which 
suggests 3-5 days of monitoring is required to reliably estimate habitual physical 
activity (Trost et al., 2005). The assessment was blinded, the armband does not provide 
any output of information to the participant. SenseWear Professional software (version 
8.0) was used to analyse the data collected. The output (Figure 2.3) included: daily 
average step count, total energy expenditure, active energy expenditure and time spent 
in domains of physical activity including: sleep, lying, sedentary (<1.5 METS), light 
(1.5-3 METS), moderate (3-6 METS), vigorous (6-9 METS) and very vigorous (>9 
METS).  
 
 
 
 
 
 
Figure 2.2 SenseWear armband worn by the participants to monitor physical activity 
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Figure 2.3 Example output derived from SenseWear armband worn by the participants 
for 4 consecutive days of habitual physical activity monitoring. 
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2.10 Dietary assessment  
In paper diary format, participants recorded their entire food and fluid intake during 
the same 4 days of physical activity monitoring. Instructions were given to provide as 
much detail as possible including timing, portion size and product branding. The detail 
of information was verified verbally with the participant on retrieval of the diary so 
that any shortage of information could be completed. Total energy consumption, 
carbohydrate, protein and fat content was determined from dietary records by a 
registered nutritionist (KM) using Nutritics (Nutrition Analysis Software for 
Professionals). 
2.11 Fasting blood profile  
Participants were cannulated in the antecubital vein of one arm and blood was drawn 
for a baseline biochemical profile. This included: fasting glucose, fasting lipids 
(cholesterol: chol; triglyceride: TG; high density lipoproteins: HDL; low density 
lipoprotein: LDL), glycated hemoglobin (HbA1c), aspartate transaminase (AST), 
alanine transaminase (ALT), and gamma-glutamyl transferase (GTT). These samples 
were analysed within 24hrs by experienced technicians in the hospital laboratory at the 
University Hospital Aintree using an Olympus AU2700 analyzer (Beckman Coulter, 
High Wycombe, UK) with standard proprietary reagents as follows: glucose with 
hexokinase, chol and HDL with cholesterol esterase/oxidase, TG with glycerol kinase, 
and liver enzymes with International Federation of Clinical Chemistry kinetic UV 
(without pyridoxal phosphate activation). LDL was calculated according to the 
Friedwald formula. 
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2.12 2 hr oral glucose tolerance test (OGTT) 
Following fasting blood samples, additional baseline (0 min) samples for glucose, 
insulin and free fatty acids were taken. The participant then underwent an OGTT; 75g 
glucose solution was consumed within 5 min and subsequent blood samples were 
drawn (from finishing the glucose solution) at 30, 60, 90 and 120 min.  
2.12.1 Glucose  
The glucose profile of the OGTT was determined within 24hrs by experienced 
technicians in the hospital laboratory at the University Hospital Aintree by the ways 
aforementioned. 
2.12.2 Insulin 
Insulin samples were centrifuged at 35,000 rpm for 15min at 4 °C and plasma stored 
at -80 °C for subsequent analysis. These samples were later analysed using a 
commercially available radio-immunoassay (Invitrogen, UK). 
2.12.3 Free fatty acids 
Free fatty acid (FFA) samples were centrifuged at 35,000 rpm for 15min at 4 °C and 
plasma stored at -80 °C for subsequent analysis. These samples were later analysed for 
FFA concentration using a non-esterified fatty acids (NEFA) assay kit (Randox 
Daytona, UK). 
2.13 Calculations of insulin sensitivity/ resistance  
2.13.1 HOMA-IR 
Using fasting plasma glucose and insulin concentrations, homeostatic model 
assessment of insulin resistance (HOMA-IR) was calculated (Matthews et al., 1985).  
HOMA-IR = (fasting insulin [µIU/ml] × fasting glucose [mmol/l]) / 22.5 
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2.13.2 Adipo-IR 
Using fasting NEFA and insulin concentrations, adipose tissue insulin resistance 
(Adipo-IR) was calculated (Gutch et al., 2015).  
Adipo-IR = fasting NEFA [mmol/l] × fasting insulin [pmol/l] 
2.13.3 Whole body insulin sensitivity (Matsuda index) 
Matsuda index was calculated to estimate whole body insulin sensitivity (Matsuda and 
DeFronzo, 1999). An Excel template was downloaded from http://mmatsuda.diabetes-
smc.jp/MIndex.html which used the following calculation: 
Matsuda index = 1000 / √G0 I0 Gmean Imean 
 I0 – Fasting plasma insulin concentration [µIU/ml], 
G0 – Fasting plasma glucose concentration [mg/dl], 
Gmean – Mean plasma glucose concentration during OGTT [mg/dl], 
Imean – Mean plasma insulin concentration during OGTT [µIU/ml], 
10,000– Simplifying constant to get numbers from 0 to 12, 
√– Correction of the nonlinear values distribution. 
2.13.4 Hepatic insulin resistance index (HIRI) 
Hepatic insulin resistance index (HIRI) was calculated by the product of the glucose 
and insulin area under curve (AUC) during the first 30 min of the OGTT (Figure 2.4) 
(Abdul-Ghani et al., 2007). The calculation is as follows.  
HIRI =  √G0−30 × I0−30   
G0-30 –Plasma glucose 0-30 min AUC concentration [mg/dl/h], 
I0-30 –Plasma insulin 0-30 min concentration [µIU/ml/h]. 
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Figure 2.4 Hepatic insulin resistance index (HIRI) derived from 0 to 30 min OGTT; 
calculated by square root of A) glucose AUC, multiplied by B) insulin AUC, expressed 
in [mg/dl/h] and [mg/dl/h] respectively. 
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2.13.5 Muscle insulin sensitivity index (MISI) 
Muscle insulin sensitivity index (MISI) was calculated from the time course of glucose 
and insulin during OGTT (Figure 2.5) (Abdul-Ghani et al., 2007).  
MISI = dG/dt ÷ Imean 
dG/dt [mmol/l/h] is the rate of decline in plasma glucose concentration and is 
calculated as the slope of the least square fit to the decline in plasma glucose 
concentration from peak to nadir. It should be noted that in some cases plasma glucose 
concentration has rebounded after it reached its nadir. In such instances, the rebound 
glucose concentration was not included in the regression. Imean [µIU/ml/h] represents 
the mean plasma insulin concentration during the OGTT. 
 
Figure 2.5 Muscle insulin sensitivity index (MISI) derived from OGTT; calculated by 
fitting a linear regression line through all the available points of glucose [mmol/l/h] 
from peak to nadir, divide absolute value of the slope by mean of all 0 to 120 min 
insulin [µIU/ml/h] measures. 
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2.14 Cardiorespiratory fitness 
Physical fitness was assessed using a cardiopulmonary exercise test (CPET) which 
measures peak oxygen consumption (V̇O2 peak). The test was performed on a treadmill 
(Model 77OCE, RAM Medisoft Group, UK) in a temperature controlled room. 
Participants wore a face mask that covered their nose and mouth (Figure 2.6) and 
provided breath-by-breath monitoring and analysis of expiratory gases and ventilation; 
electrocardiographic monitoring was also conducted (Love Medical Cardiopulmonary 
Diagnostics, UK). Gas analysers and flow probes were calibrated prior to the test. The 
modified Bruce protocol was employed; after an initial 2 min warm up at 2.2 kph on a 
flat gradient, step-wise increments in speed and gradient were employed each minute 
(Bruce et al., 1973). The participants’ rate of perceived exertion (RPE) (Borg, 1982) 
(Borg, 1982) (Borg, 1982) (Borg, 1982) was taken every minute. V̇O2 peak was 
determined as plateau in V̇O2 (l/min) and/or respiratory exchange ratio >1.15 
combined with heart rate >90% predicted maximum (Miller et al., 1993). If volitional 
exhaustion occurred, the highest V̇O2 peak value in the minute prior was taken. An 
example output of the CPET is shown in figure 2.7, the blue line displaying a plateau 
of V̇O2. Breath-by-breath data was exported for calculations of absolute V̇O2 and 
calculations were derived relative to overall body mass, lean and fat free mass. 
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Figure 2.6 A participant set up for assessment of cardiorespiratory fitness (peak 
oxygen consumption, V̇O2 peak). 
Figure 2.7 Example monitoring of cardiopulmonary exercise test (CPET) measuring 
peak oxygen consumption (V̇O2 peak). Blue line, peak oxygen consumption (V̇O2); 
red line, peak carbon dioxide consumption (V̇CO2), brown line, ventilatory 
equivalents (VE), purple line, heart rate (HR). 
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2.15 Dual-energy x-ray absorptiometry (DXA) 
Whole body scans were performed using DXA (Lunar iDXA, GE Healthcare, UK) to 
determine body fat and lean body mass. All participants were placed in the standard 
supine scanning position in line with manufacturers guidelines (in the centre of the 
scanning bed with their head facing forwards, arms slightly away from the body, palms 
facing upwards and legs slightly apart with natural external rotation and toes facing 
upwards). Each scan session was preceded by a calibration routine, using multiple 
quality-control phantoms that simulate soft tissue and bone. Data output (Figure 2.8) 
was analysed using Lunar iDXA software (version 13.60.033), regional and limb 
specific quantifications of fat and lean tissue were given. 
 
Figure 2.8 Example date output from dual-energy x-ray absorptiometry (DXA) 
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2.16 Magnetic resonance imaging and spectroscopy  
MR scanning was performed at LiMRIC. The participants wore a patient gown and 
removed metal objects. The scans were conducted by two experienced radiographers; 
protocols and participant positioning were standardised. 
2.16.1 Whole body imaging - adipose tissue volume and distribution  
MRI was performed on 1.5T Siemens Symphony scanner (Siemens Medical Solutions, 
Erlangen, Germany). Total body subcutaneous adipose tissue (SAT), abdominal SAT 
(abSAT) and visceral adipose tissue (VAT) were calculated from whole body axial 
T1-weighted fast spin echo scans (axial scans, 10mm slice thickness followed by a 
10mm gap using the integral body coil). Figure 2.9 displays one trans-axial image of 
abdomen, SAT is represented as green and VAT red. The abdominal region was 
defined as the image slices from the slice containing the femoral heads, to the slice 
containing the top of the liver/base of the lungs. All MRI scans were analysed by 
Vardis Group Inc. (London, UK) using SliceOMatic (Tomovision, Montreal, Canada); 
data were anonymized prior to analysis ensuring blindness to all clinical details. 
 
 
 
 
 
 
Figure 2.9 One trans-axial image of abdomen, subcutaneous adipose tissue (SAT) is 
represented as green and visceral adipose tissue (VAT) as red. 
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2.16.2 1H magnetic resonance spectroscopy (1H-MRS) - liver and skeletal muscle  
1H-MRS was performed on 1.5T Siemens Symphony scanner (Siemens Medical 
Solutions, Erlangen, Germany). In the liver, three voxels of interest were identified at 
standard sites avoiding ducts and vasculature (Figure 2.10). In skeletal muscle, a single 
voxel was identified in each of the tibialis anterior (TA) and soleus (Sol) muscles, 
avoiding bone, fascia and the neurovascular bundle (Figure 2.11). Single voxel 
spectroscopy was conducted at each of these five sites. Voxel size was 20×20×20 mm, 
echo time (TE) 135 ms, repetition time (TR) 1500 ms, with 64 acquisitions. Where the 
musculature was too small to allow placement of a 20 mm voxel, a 15×15×20 mm 
voxel was placed and the number of acquisitions was increased to 200 to maintain 
signal-to-noise ratio. 1H-MR spectra were quantified by Professor Kemp using the 
AMARES algorithm in the software package Java-based Magnetic Resonance User 
Interface (jMRUI-3.0) (Naressi et al., 2001). Intrahepatocellular lipid (IHCL) is 
expressed as percent of CH2 lipid signal amplitude relative to water signal amplitude 
after correcting for T1 and T2 (Thomas et al., 2005), and intramyocellular lipid (IMCL) 
is expressed as CH2 lipid amplitude relative to total creatine amplitude after correcting 
for T1 and T2 (Rico-Sanz et al., 1999). 
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Figure 2.10 Example of a participant with high liver fat and voxel positions used during spectroscopy. 
Figure 2.11 Example of the voxel positions used for soleus (left) and tibialis anterior (right) during spectroscopy. 
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2.16.3 31P MRS - skeletal muscle mitochondrial function  
31P-MRS assessments of mitochondrial function in skeletal muscle were carried out 
using a Siemens 3T Trio MR scanner (Siemens AG, Erlangen, Germany). An isometric 
knee extension exercise protocol was employed as previously described (Cuthbertson 
et al., 2014). In brief, participants lay supine, with the right knee flexed over a rigid 
foam support in a custom-built rig permitting isometric knee extension exercise against 
a strap across the anterior lower shin/ankle connected to an aluminium bar fitted with 
a strain gauge (Figure 2.12). The exercise protocol consisted of 1.1 min rest followed 
by 2 bouts of knee extension isometric exercise each followed by 5.2 min recovery 
periods. The first bout of exercise corresponded to 70% maximal voluntary contraction 
(MVC) and lasted 3.2 min. The second bout of exercise corresponded to 90% MVC 
and lasted 2 min. The knee extension exercise was paced at 0.25 Hz (2s on, 2s off) by 
an audible cue during each exercise. The contraction force was fed back visual via an 
LED display. 31P-MRS data were processed using AMARES time-domain fitting 
algorithm in jMRUI-3.0. The chemical shift of the inorganic phosphate (Pi) peak 
relative to phosphocreatine (PCr) (σ parts per million) was used to determine 
intracellular pH. PCr recovery time courses were fitted to a monoexponential function 
to determine the recovery rate constant (k/min). Figure 2.13 displays an example of 
resting spectra (high Pi, low PCr) top right and two spectra following exercise (reduced 
Pi, increased PCr). For an indepth review see Kemp et al. (Kemp et al., 2015).   
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Figure 2.12 A participant set up for 31P magnetic resonance spectroscopy, an isometric 
knee extension exercise protocol to assess skeletal muscle mitochondrial function. 
Figure 2.13 Example spectra derived from 31P magnetic resonance spectroscopy. Top 
left, resting (high inorganic phosphate [Pi], low phosphocreatine [PCr]); top right, 
following 70% maximal voluntary contraction (MVC), (depleted Pi and increased 
PCr); bottom left, following 90% MVC (further depleted Pi and increased PCr); 
bottom right, spectra positioning within the quadriceps. 
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2.17 Tissue biopsies  
Tissue biopsies were performed by experienced clinical staff in strictly sterile 
conditions. Samples were processed and stored by KBD. Please note, these specimen 
are still to be analysed and are not included in the thesis. 
2.17.1 Skeletal muscle (SkM) biopsy 
Skeletal Muscle samples were obtained from the right leg (vastus lateralis) using the 
conchotome technique. In brief, local anaesthetic (1% lidocaine) was administered 
before a 1cm incision was made. The samples were taken using 4.5mm jaw forceps 
(Tilley Henckel Punch, UK). Immediately after collection, the samples were a) snap 
frozen in liquid nitrogen and b) embedded on cork into Tissue Tek optimum cutting 
temperature (OCT) compound (Sakura Finetek, Netherlands) and immediately frozen 
in liquid nitrogen cooled isopentane (Sigma Aldrich, USA) (Figure 2.14). Embedded 
samples were initially blotted to remove excess blood and any visible collagen or fat 
was discarded. All muscle samples were stored at -80°C.  
 
 
Figure 2.14 Skeletal muscle (SkM) specimen taken from vastus lateralis biopsy, 
before processing (right) and following embedding and freezing in liquid nitrogen 
cooled isopentane (left). 
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2.17.2 Subcutaneous adipose tissue (SAT) biopsy  
Subcutaneous adipose tissue samples were obtained from the anterior abdominal wall 
approximately 2 cm lateral to the umbilicus. Local anaesthetic (2% lidocaine with 
adrenaline 1:200,000) was administered before a 1cm incision was made. The samples 
were taken using 15mm pincher forceps (Adsons, UK). Immediately after collection, 
the samples (Figure 2.15) were a) snap frozen in liquid nitrogen and stored at -80°C 
and b) submerged in 10% formaldehyde solution (Sigma Aldrich, USA) and stored at 
+4°C. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15 Subcutaneous adipose tissue (SAT) specimen taken from abdominal 
biopsy and stored in 10% formaldehyde solution. 
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Chapter 3.  
Habitual physical activity does not explain differences in 
metabolic health status in obese and non-obese groups 
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3.1 Introduction  
Obesity (body mass index; BMI ≥30 kg/m2) is strongly associated with 
cardiometabolic health and overall mortality (Berrington de Gonzalez et al., 2010). 
However, not all obese individuals are ‘unhealthy’ (Phillips, 2017) and likewise not 
all non-obese individuals are ‘healthy’ (Stefan et al., 2017). Meta-analysis data 
suggests that higher cardiorespiratory fitness (CRF), largely a product of greater 
physical activity (PA), can reduce mortality risk regardless of BMI (Barry et al., 2014); 
a higher CRF has been reported in metabolically healthy obese (MHO) (Ortega et al., 
2013). Globally, the beneficial role of PA against cardiometabolic complications is 
recognised where the degree of benefit can be relative to the PA intensity (Warburton 
and Bredin, 2017). However, the support for PA as a determinant of health status 
within obese and non-obese groups is equivocal.   
The stability of MHO and metabolically unhealthy non-obese (MUNO) is challenged 
and granted these phenotypes can appear as transient states. In a 20 year follow up 
study, it was found that one-half of MHO had made an adverse transition to 
metabolically unhealthy obese (MUO) and were also more likely to make this 
transition than MUNO (Bell et al., 2015a). Nevertheless, the prevalence of these ‘non-
conventional’ phenotypes (i.e. MHO and MUNO) cannot be disregarded. The 
definition of metabolic health across previous studies has not been consistent however 
general characterisation of these groups has. MHO individuals display favourable 
insulin sensitivity, fat distribution (less visceral and ectopic fat), and cardiovascular 
function (Phillips, 2017). MUNO display less favourable features including adipose 
tissue dysfunction and a body composition whereby the anatomical site of fat storage 
appears to be more important than total amount of body fat (Stefan et al., 2017). 
Although MHO exhibit a cardiometabolic profile similar to metabolically healthy non-
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obese (MHNO) their risk of CVD is greater (Caleyachetty et al., 2017). The clinical 
value of understanding the protective features of these phenotypes stands.  
Previous research has suggested that a metabolically unhealthy individual may present 
as a consequence of low PA (Bell et al., 2015b, Camhi et al., 2015) whereas other 
research has not (Hankinson et al., 2013, Bell et al., 2014b, Phillips et al., 2013). Due 
to differences in methodology, cohorts and definitions these studies do not well define 
the PA characteristics between phenotypes. There is a growing recognition that 
sedentary behaviour has an independent association on metabolic health (Knaeps et 
al., 2016, Bell et al., 2014a). The role of sedentary behaviour has been objectively 
investigated within these phenotypes in older adults only (Bell et al., 2014b). However, 
age is an independent correlate of cardiometabolic abnormalities among non-obese 
and obese individuals (Wildman et al., 2008). Public health guidelines state that an 
individual should engage in 150 minutes of moderate-vigorous PA (MVPA) per week 
and historically research has focused on this. Bell and collegues found no difference 
between MHO and MUO in the likelihood of meeting MVPA recommendations (Bell 
et al., 2015b).  Through objective monitoring of PA, which improves reliability 
compared to self-report (Dyrstad et al., 2014), would provide a comprehensive account 
of total daily activity which includes both sedentary behaviour and MVPA.  
The aim of this cross-sectional study is to explore whether habitual PA and sedentary 
behaviour explains differences in metabolic health status of individuals of similar 
BMI. It is hypothesised that lower levels of PA and higher levels of sedentary time 
will be observed in unhealthy individuals irrespective of BMI.   
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3.2 Methods 
Information regarding recruitment, screening, ethics and assessment measures be 
found in Chapter 2, General methodology.  
3.2.1 Participants 
Individuals with any level of physical activity were eligible. Participants were screened 
for and then, where appropriate, consented. Ninety-eight individuals (52 male, 46 
female) with a mean age of 39 ± 13 years and BMI 27 ± 5 kg/m2 were recruited.  
3.2.2 Research design  
All participants completed an assessment of habitual physical activity and dietary 
consumption over a period of 4 days (including one weekend day). This was followed 
by two assessment visits. The first at University Hospital Aintree involved 
anthropometry, fasting bloods, oral glucose tolerance test (OGTT) and assessment of 
CRF (V̇O2 peak). The second at University of Liverpool comprised of magnetic 
resonance imaging (MRI) and proton magnetic resonance spectroscopy (1H-MRS). 
Due to technical issues during a period of this investigation MRI quantification of body 
fat was conducted on only 72 individuals. Bio-impedance data was collected in all 
individuals whereby V̇O2 peak calculations were based on both total body mass and 
fat free mass.  
3.2.3 Individual phenotyping  
Individuals were characterised into one of four groups based on their obesity (WHO 
classification, Table 1.1) and metabolic health status (International Diabetes 
Federation (IDF) criteria of metabolic syndrome (MS), Table 2.1); terms used herein 
i) ‘healthy non-obese’, ii) ‘unhealthy non-obese’, iii) ‘healthy obese’ and iv) 
‘unhealthy obese’.  
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3.2.4 Sample size 
This study was powered on the basis of collecting tissue samples for  a mechanistic 
study, based on previously published data this was calculated for 12 in each group. 
However, for the data presented here all eligible participants that had attended the 
University of Liverpool laboratories during data collection period were included. This 
explains the large n value of healthy non-obese, important to note is that this group 
was homogeneous and therefore was unlikely to introduce bias.  
3.2.5 Statistical analysis  
All data were explored for normality using visual inspection of frequency distributions, 
and transformed using 1og10 or logsqr, where appropriate. Age was analysed using a 
one factor between-groups analysis of variance (ANOVA) whereby a significant group 
effect was observed (P<0.05). Between-group univariate general linear models were 
conducted for all other variables, with age as a covariate. Statistically significant 
interactions were explored using the least significant difference (LSD) approach to 
multiple pairwise comparisons. The alpha level of statistical significance was set at 
P<0.05. Data are presented as mean (95% confidence intervals [CI]), unless stated 
otherwise, and exact P values are cited (values of P of “0.000” provided by the 
statistics package are reported as “<0.0005”). Transformed data were back 
transformed to original units and presented as mean (95% CI). Statistical analysis was 
performed using Statistical Package for Social Sciences (SPSS) for Windows (Version 
24.0, SPSS Inc., Chicago, IL, USA) statistic software package. 
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3.3 Results 
3.3.1 Participant characteristics 
Group characteristics are tabulated (Table 3.1). All significant differences between the 
groups’ components of metabolic syndrome were in line with IDF classification, i.e. 
those who were healthy had favourable IDF-related health parameters compared to 
those that were unhealthy. The obese groups were well matched for age and BMI. The 
unhealthy non-obese were on average 15 (7, 22) years older and had a BMI of 3 (1, 5) 
kg/m2 greater than healthy non-obese.  
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Table 3.1 Clinical, biochemical and metabolic characteristics of study participants categorised for obesity and subsequently for metabolic health.  
WC, waist circumference *Europiod cut off; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein 
cholesterol; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; abSAT, abdominal SAT. 
 Non-obese Obese 
 MetS- (n=62) MetS+ (n=11) P value MetS-(n=12) MetS+ (n=13) P value 
Gender M n=30; F n=32 M n=9; F n=2 0.042 M n=5; F n=7 M n=8; F  n=5 0.319 
Age (years) 34 (31, 38) 49 (43, 55) <0.0005 45 (39, 50) 46 (39, 52) 0.902 
Weight (kg) 70.8 (68.1, 73.6) 80.8 (75.7, 85.9) 0.045 96.3 (85.2, 107.4) 99.8 (91.7, 107.9) 0.470 
BMI (kg/m2) 24.1 (23.4, 24.8) 26.9 (25.7, 28.2) 0.018 33.7 (30.6, 36.7) 34.1 (32.6, 35.6)  0.722 
Components of metabolic syndrome [risk cut off] 
WC (cm) [M ≥94; F ≥80*] 85 (82, 87) 98 (93, 102) 0.005 105 (96, 115) 111 (106, 116) 0.191 
SBP (mmHg) [≥130] 120 (117, 123) 144 (137, 151) <0.0005 126 (117, 135) 147 (135, 158) <0.0005 
DBP (mmHg) [≥85] 75 (72, 77) 95 (85, 105) <0.0005 77 (73, 80) 90 (82, 98) 0.001 
Fasting glucose (mmol/l) [≥5.6] 4.9 (4.8, 5.0) 5.4 (5.1, 5.6) 0.076 5.0 (4.7, 5.2) 5.7 (5.0, 6.4) 0.003 
Triglycerides (mmol/l) [≥1.7] 0.9 (0.8, 1.1) 1.5 (1.0, 1.9) 0.080 1.2 (0.6, 1.7) 1.8 (1.3, 2.4) 0.016 
HDL-C (mmol/l) [M <1.0; F <1.3] 1.8 (1.7, 1.9) 1.7 (1.2, 2.1) 0.527 1.6 (1.3, 2.0) 1.3 (1.6, 1.8) 0.133 
MRI derived body composition                 n=48                         n=8                                                   n=8                          n=8 
Total body fat (l) 21.3 (18.9, 23.7) 25.8 (20.1, 31.5) 0.164 39.6 (33.6, 45.6) 39.1 (33.2, 44.7) 0.882 
Total SAT (l) 16.5 (14.2, 18.8) 18.6 (13.1, 24.1) 0.492 30.5 (24.7, 36.3) 28.2 (22.7, 33.8) 0.562 
Total internal fat (l) 4.7 (4.1, 5.4) 7.3 (5.7, 8.9) 0.006 9.2 (7.5, 10.9) 8.5 (6.9, 10.2)  0.552 
Abdominal SAT (l) 4.5 (3.5, 5.5) 5.7 (3.3, 8.1) 0.374 9.7 (7.2, 12.3) 12.1 (9.7, 14.6) 0.162 
VAT (l) 2.3 (1.9, 2.8) 4.2 (3.1, 5.2) 0.002 5.2 (4.1, 6.2) 5.7 (4.5, 6.8) 0.490 
VAT: abSAT ratio 0.6 (0.5, 0.7) 0.7 (0.5, 0.9) 0.333 0.6 (0.4, 0.8) 0.6 (0.4, 0.8) 0.793 
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3.3.2 Dietary analysis 
Total energy consumption, carbohydrate, protein and fat was not different between 
groups (P=0.926, P=0.581, P=0.342, P=0.731). Mean ±SD macronutrient percentages 
were 56±16% carbohydrate, 24±9% protein, and 20±7% fat. 
3.3.3 Cardiorespiratory fitness 
A significant group effect for cardiorespiratory fitness was evident (P<0.0005). 
Unhealthy obese individuals displayed significantly lower fitness than all other groups 
(P≤0.039; mean difference ≥5.8 ml/min/kg). When accounting for fat free mass (bio-
impedance derived), unhealthy obese individuals displayed significantly lower values 
than both healthy groups (P≤0.012; mean difference ≥7.5 ml/min/kg) but not 
unhealthy non-obese (P=0.113; mean difference 5.9 ml/min/kg) (Figure 3.1A). No 
significant difference in either cardiorespiratory measure was observed in both non-
obese groups and healthy obese (P≥0.080).  
3.3.4 MRI quantification of body fat 
Total body fat and total SAT was not statistically different between the two non-obese 
groups (P=0.164 and P=0.492, respectively) or the two obese groups (P=0.882 and 
P=0.562, respectively). As expected, the obese groups had significantly greater 
volumes of total body fat and total SAT than non-obese groups. Total internal fat was 
significantly lower in the healthy non-obese group than any other group (P≤0.006; 
mean difference ≥2.8 l), the three other groups were not significantly different 
(P≥0.103). Abdominal SAT values were again as expected, such that there was no 
significant difference between the two non-obese groups (P=0.374) or the two obese 
groups (P=0.162) and the obese groups had significantly greater volumes overall. VAT 
was significantly lower in the healthy non-obese group than any other group (P≤0.002; 
mean difference ≥1.9 l). The obese groups have statistically similar amounts VAT 
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(P=0.490). Of note, in unhealthy non-obese individuals VAT was significantly lower 
than unhealthy obese (P=0.047) but not healthy obese (P=0.173). VAT to abdominal 
SAT ratio is not significantly different between the groups (P=0.776). The 
demographics of those who had MRI versus those who did not was not statistically 
different (Appendix; Table 8.1).  
3.3.5 MRS quantification liver fat and intramuscular fat 
There was a significant group effect for liver fat percentage (P<0.0005) (Figure 3.1D). 
Healthy non-obese individuals had significantly lower liver fat % than all other groups 
(P≤0.050; mean difference ≥2.1 %). Unhealthy non-obese were not significantly 
different to either obese group (P≥0.132; mean difference ≥0.6 %); however, healthy 
obese was significantly lower than unhealthy obese (P=0.049; mean difference 2.6 %). 
There was no significant group effect for intramuscular fat % (P=0.336).  
3.3.6 Glucose metabolism 
A significant group effect was found for whole body insulin sensitivity quantified by 
Matsuda index (P=0.002) (Figure 3.1B). Healthy non-obese individuals demonstrated 
greater levels of insulin sensitivity than either of the other groups (P≤0.024; mean 
difference ≥1.6). No significant difference between Matsuda index in healthy obese 
and both unhealthy groups was observed (P≥0.562). There was no significant group 
effect of muscle insulin sensitivity index (P=0.220) or hepatic insulin resistance index 
(P=0.128). However when exploring the data, unhealthy obese had significantly 
greater hepatic insulin resistance than healthy non-obese (P=0.028; mean difference 
7.7) (Figure 3.1C). HOMA-IR was significantly lower in healthy non-obese than both 
obese groups (P≤0.026; mean difference ≥1.7) but not unhealthy non-obese (P=0.092; 
mean difference 1.4). HOMA-IR was not significantly different between healthy obese 
and both unhealthy groups (P≥0.713).  
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3.3.7 Lipid metabolism  
There was no significant group effect for total cholesterol and LDL cholesterol 
(P=0.426, P=0.408 respectively). Total cholesterol: HDL ratio was significantly 
different between groups. Healthy non-obese had a significantly lower ratio than both 
unhealthy groups (P≤0.025; mean difference ≥0.8) but not healthy obese (P=0.597; 
mean difference 0.2). Healthy obese had a significantly lower ratio than unhealthy 
obese (P=0.001) but not unhealthy non-obese (P=0.137); there was no significant 
difference between the two unhealthy groups (P=0.092). 
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Figure 3.1 Age and BMI controlled A) V̇O2 peak relative to fat free mass (FFM), B) whole body insulin sensitivity, C) hepatic insulin resistance 
and D) liver intrahepatocellular lipid (IHCL) fat in healthy non-obese, healthy obese, unhealthy non-obese and unhealthy obese (left to right of 
each graph), solid bars represent non-obese individuals, open bars represent obese individuals, * denotes significantly lower liver IHCL in healthy 
non-obese than all other groups. 
71 
 
3.3.8 Physical activity  
Average daily steps 
A significant group effect was found for average daily steps (P=0.041) (Figure 3.2A). 
Healthy non-obese had significantly greater daily average steps than both unhealthy 
groups (P≤0.050; mean difference ≥2155 steps/day), and there was a non-significant 
trend for when compared with the healthy obese (P=0.092; mean difference 1840 
steps/day). There was no significant difference between healthy obese and both 
unhealthy groups (P≥0.510). 
Daily sedentary time  
A significant group effect was found for daily sedentary time (P=0.002) (Figure 3.2B). 
Sedentary time was similar between both non-obese groups (P=0.267; 47 min/day) 
and both obese groups (P=0.263; 57 min/day). Unhealthy obese individuals displayed 
significantly greater daily sedentary time than both non-obese groups (P≤0.045; mean 
difference ≥107 min/day). Moreover, healthy obese individuals had significantly 
greater daily sedentary time than healthy non-obese (P=0.002; 97 min/day) but not 
unhealthy non-obese (P=0.348; 50 min/day).  
Sleep duration and daily lying time  
There was no significant group effect for amount of time spent lying (P=0.080) or 
sleeping (P=0.117). When removing sleep duration from overall daily sedentary time, 
a significant group effect remained (P=0.023) whereby healthy non-obese individuals 
displayed significantly lower values than both obese groups (P≤0.033) but not 
unhealthy non-obese (P=0.245); there was no significant difference between healthy 
obese and both unhealthy groups (P≥0.238). There was no significant difference 
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between the groups when subtracting lying time from overall daily sedentary time 
(P=0.084).  
Daily light activity  
A significant group effect was found for daily light activity (P=0.001) (Figure 3.2C).  
There was no significant difference in daily light activity between both non-obese 
groups (P=0.711; mean difference 10 min/day) and both obese groups (P=0.771; 9 
min/day). However, both obese groups displayed significantly less light activity time 
than both non-obese groups (P≤0.036; mean difference ≥69 min/day).  
Daily moderate-vigorous activity  
There was no significant difference between the groups moderate-vigorous activity 
(P=0.322) (Figure 3.2D). When exploring moderate and vigorous activity 
independently, the group effect was similar for moderate activity (P=0.646) and 
statistically different for vigorous activity (P=0.015). Healthy non-obese individuals 
performed significantly greater duration of vigorous activity than both obese groups 
(P≤0.039; mean difference ≥16 min/day) but not unhealthy non-obese (P=0.079; mean 
difference 14 min/day). Vigorous activity was not significantly different between 
healthy obese and both unhealthy groups (P≥0.440). 
Average daily METS and PA duration 
Daily average METS and physical activity duration had significant group effects 
(P<0.0005 and P=0.020, respectively); for both measures, healthy non-obese had 
significantly greater values than both obese groups, but were not significantly different 
to unhealthy non-obese. Daily average METS in healthy non-obese were 0.3 METS 
greater than both obese groups (P<0.0005). The same trend was observed for PA 
duration, with healthy non-obese displaying significantly greater duration that both 
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obese groups (P≤0.018; mean difference ≥107 min/day). There was no significant 
difference between healthy obese and both unhealthy groups for average daily METS 
and PA duration (P≥0.079 and P ≥0.450 respectively).  
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Figure 3.2 Age and BMI controlled A) average daily steps, B) sedentary time, C) light activity, D) moderate-vigorous activity, E) daily metabolic 
equivalents (METS) and F) physical activity (PA) duration in healthy non-obese, healthy obese, unhealthy non-obese and unhealthy obese (left to 
right of each graph), solid bars represent non-obese individuals, open bars represent obese individuals.
75 
 
3.4 Discussion  
This study is the first to objectively monitor PA and sedentary behaviour in young to 
middle aged adults who have been categorised for metabolic health and obesity status.  
The major finding of the current study was that habitual PA, including MVPA and 
sedentary behaviour did not explain differences in metabolic health status of 
individuals of similar BMI. Greater daily sedentary time and less light activity was 
associated with obesity but MVPA had no significant effect. CRF was markedly lower 
in unhealthy obese, however, when FFM was accounted the unhealthy obese and non-
obese groups were similar.  
The hypothesis of lower levels of PA and higher levels of sedentary time in unhealthy 
individuals irrespective of BMI, can be rejected in the current cohort. There are other 
studies that report a lack of association in these phenotypes for PA generally (Phillips 
et al., 2013) and for sedentary behaviour (Hankinson et al., 2013, Bell et al., 2014b). 
Contrary to these findings, a study in over 3,000 older adults, total PA was greater in 
healthy individuals across BMI groups (Bell et al., 2015b) and in a smaller study of 
young women healthy obese individuals demonstrated more time in light PA and less 
sedentary behaviour than their unhealthy counterparts (Camhi et al., 2015). Whilst 
prospective studies have shown that these phenotypes can be transient (Bell et al., 
2015a) there is evidence to suggest that PA levels may (Moon et al., 2017) or may not 
(Hamer et al., 2015) play a protective role. Due to differences in methodology, cohorts 
and definitions it is difficult to directly compare the literature. Ethnicity can influence 
the cardiometabolic abnormalities in these groups (Wildman et al., 2008) therefore the 
IDF criteria of MetS was chosen in the current investigation which accounts for ethnic 
differences in waist circumference risk (Alberti et al., 2009). Despite several 
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investigations, robust evidence for a significant role of PA and sedentary behaviour in 
determining metabolic health status irrespective of BMI is lacking. 
Healthy obesity remains a contentious topic, however the findings of current 
investigation do support the overall beneficial effect of increased PA and reduced 
sedentary behaviour. Those who were obese had more sedentary time and less light 
activity time however this association is not new (Hamer et al., 2013, Kim et al., 2013). 
The observed PA levels in unhealthy non-obese are worthy of discussion. Sedentary 
time has an independent association with metabolic health (Knaeps et al., 2016, Bell 
et al., 2014a); similar sedentary time in unhealthy non-obese and both obese groups 
supports this. When compared to healthy non-obese, daily average steps were 
significantly lower in both unhealthy groups and thus may explain their unfavourable 
health profile; the healthy groups had similar average daily steps further suggesting a 
protective role. MVPA was not significantly different between the groups and 
historically research has focused on these recommendations (i.e. exercise). This 
research offers an alternative approach as habitual physical activity (i.e. not exercise). 
CRF was markedly lower in both unhealthy groups when accounting for FFM; low 
CRF can increase mortality risk regardless of BMI (Barry et al., 2014). In line with 
these data a higher CRF has been previously reported in healthy groups (Ortega et al., 
2013). Taken together with the strong association of PA with a higher CRF (Warburton 
and Bredin, 2017) this study outlines the overall benefits of increased PA and reduced 
sedentary behaviour. 
When compared to both obese groups, unhealthy non-obese individuals displayed 
similar levels of liver fat, whole body insulin sensitivity and hepatic insulin resistance 
therefore BMI cannot be the sole explanation. Of note, unhealthy obese had 
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significantly more liver fat than their healthy counterpart. These characteristics have 
been previously observed (Phillips, 2017, Stefan et al., 2017). Former research has 
suggested that ectopic fat may be a paramount target for reduction of disease risk and 
perhaps more important than traditional risk factors (Arsenault et al., 2012). A more 
favourable fat distribution has been associated with a healthy profile in obese adults 
over a period of 10 years and reduces the risk of T2D and CVD (Appleton et al., 2013). 
Liver fat has been proposed as a better marker of metabolic health than visceral fat 
(Fabbrini et al., 2009) and recently as an independent risk factor for progression from 
a healthy to unhealthy phenotype, even in non-obese individuals (Hashimoto et al., 
2017). Exploring the relationship between liver fat and habitual PA, including detailed 
characterisation of domains of activity (i.e. sedentary time, light activity and MVPA) 
may provide insight for innovative PA guidelines. 
The strengths of this study include the objective monitoring of PA (more valid than 
self-report (Dyrstad et al., 2014) which has provided detailed phenotyping and 
comprehensive assessments in young to middle aged adults who have not previously 
been studied. The limitations include sample size, duration of PA assessment (4 days 
which may induce bias towards week days, we ensured that at least one weekend day 
was monitored) and cross-sectional design which cannot determine causality. 
Objective PA monitoring in a larger cohort with prospective design is required. 
Important to note is that clinical studies, particually observational, can introduce, by 
an interaction effect of the research, behaviours that are not typical of daily living 
(Hammond and Wellington, 2013). In this instance participants may have altered their 
physical activity levels knowing this was being assessed. However, this is likely to be 
consistent across the groups. Knowing that the cardiometabolic complications can be 
altered in normal-weight and overweight; future research should study these 
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classifications separately as opposed to non-obese in the current study. Likewise, 
unhealthy were categorised as 3 or more MetS components and those otherwise were 
healthy; recent research suggests the use of a refined healthy reference group with only 
0-1 factors (Hamer et al., 2017).  
In summary, habitual physical activity does not explain differences in metabolic health 
status in obese and non-obese groups’, daily average steps may have an influence but 
this requires further investigation. In concordance with previous research, greater 
amounts of sedentary time and less daily light activity are evident in obese individuals. 
Overall, this research offers an alternative approach as habitual physical activity (i.e. 
not exercise and/or sedentary time) may have an effect that is independent of MVPA. 
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associated with liver fat in a combined cohort of obese and 
non-obese adults 
 
List of authors: Bowden Davies, K. A., Sprung, V. S., Norman, J. A., Irwin, A. J., 
Adams, V. A., Thompson, A.,  Mitchell, K.L., Wilding, J. P. H., Kemp, G. J., & 
Cuthbertson, D. J.   
KBD specific contribution to the study: Design, ethical approval and set up of the 
study, recruitment and participant management, coordination of testing visits including 
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4.1 Introduction  
Strong evidence suggests that non-alcoholic fatty liver disease (NAFLD) substantially 
increases the risk of developing type 2 diabetes mellitus (T2D) and cardiovascular 
disease (CVD). A greater body mass index (BMI), body fat distribution (visceral 
versus subcutaneous), insulin resistance and higher circulatory lipids have all been 
associated with the development of NAFLD (Rinella, 2015). The role of physical 
activity (PA) in the prevention of liver fat in the context of non-alcoholic fatty liver 
disease (NAFLD) has been well studied and recently reviewed (Qiu et al., 2017, 
Romero-Gómez et al., 2017, Zelber-Sagi et al., 2016). However, an independent 
association between sedentary behaviour and NAFLD is emerging, such that PA and 
sedentary behaviour ought to be viewed separately.  
Ryu and colleagues (Ryu et al., 2015) conducted a large cohort study which supports 
the importance of reducing time spent sedentary in addition to promoting PA. 
However, these authors utilised PA questionnaires and measured liver fat using 
ultrasonography. Objective PA monitors are superior to questionnaires as they reduce 
reporter bias (Dyrstad et al., 2014) and proton magnetic resonance spectroscopy (1H-
MRS) is a more sensitive and quantitative method of determining liver fat 
(Szczepaniak et al., 2005). Whilst smaller studies have objectively monitored PA and 
quantified liver fat using MRS the application of their findings are limited due to a) no 
liver fat measurement in control individuals (Hallsworth et al., 2015) and b) 
overweight and obese individuals being studied (Keating et al., 2016).  
It is recognised that liver steatosis (the initial stage of NAFLD) should be targeted 
early to prevent complications associated with the progression of this condition. The 
majority of previous research has characterised those with and without NAFLD which 
has not well defined the PA behaviours of those that should be targeted, i.e. healthy 
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individuals before harmful levels of liver fat accumulate. Characterising the PA 
behaviours of healthy individuals provides important knowledge for changing 
behaviours associated with the risk of increased liver fat. One study has objectively 
measured PA in a community based cohort (Long et al., 2015) but again sub-optimal 
methods were used to determine liver fat. Objective investigation of PA and sedentary 
behaviour in a community based cohort utilising MRS assessment of liver fat is 
warranted. 
The primary aim of this study was use objective monitoring of PA and sedentary 
behaviour to investigate relationships between domains of physical activity and MRS 
quantified liver fat, in healthy individuals. Knowing that insulin resistance and BMI 
are strongly associated with the development of fatty liver, secondary aims were to 
investigate their association with PA and sedentary behaviour also.   
4.2 Methods  
Information regarding recruitment, screening, ethics and assessment measures be 
found in Chapter 2, General methodology.  
4.2.1 Participants 
The individuals studied here are the cohort of Chapter 3. Of note, none of the 
individuals were clinically diagnosed with NAFLD on consent.  
4.2.2 Research design 
Participation included assessment of habitual physical activity and dietary 
consumption over a period of 4 days including one weekend day. There were two 
subsequent assessment visits, one at University Hospital Aintree including fasting 
bloods, oral glucose tolerance test (OGTT) and assessment of cardiorespiratory fitness 
(CRF) as well as one at University of Liverpool including proton magnetic resonance 
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spectroscopy (1H-MRS). V̇O2 peak (CRF) was calculated from bio-impedance derived 
total body mass and fat free mass (FFM).  
4.2.3 Statistical analysis  
All data were explored for normality using visual inspection of frequency distributions, 
and transformed using 1og10 where appropriate. Univariate and multivariate linear 
regression were used to analyse components of physical activity and fitness associated 
with the outcome measure of interest. All variables reaching P<0.05 in univariate 
analysis were carried forward to a multivariate model. An a priori decision was made 
to include age and BMI in all multivariate models. The alpha level of statistical 
significance was set at P<0.05. Data are presented as mean (95% confidence intervals 
[CI]), unless stated otherwise and exact P values are cited (values of P of “0.000” 
provided by the statistics package are reported as “<0.0005”). Transformed data were 
back transformed to original units and presented as mean (95% CI). Pearson’s 
correlation coefficient was performed to generate R2 in order to determine the 
proportion of the variance in the dependent variable that is predictable from the 
independent variable. The strength of correlations are determined by Field 
classification (Field, 2013). Statistical analysis was performed using Statistical 
Package for Social Sciences (SPSS) for Windows (Version 24.0, SPSS Inc., Chicago, 
IL, USA) statistic software package. 
4.3 Results 
4.3.1 Participant characteristics 
Participant characteristics are summised in Table 4.1. The number of individuals with 
each risk factor is summarised in Table 4.2.  Overall, 74 individuals were categorised 
as metabolically healthy and 24 metabolically unhealthy (classified as 3 or more risk 
83 
 
factors for metabolic syndrome). Mean whole body insulin sensitivity (Matsuda index) 
of all individuals was 3.3 (2.8, 3.7). Of note, 27% of individuals had liver fat >5% 
Table 4.1 Participant characteristics of healthy versus unhealthy individuals. 
 Healthy Unhealthy P value 
Gender M n=35; F n=39 M n=17; F n=7 0.141 
Age (years) 36 (33, 39) 47 (43, 51) <0.0005 
Weight (kg) 74.9 (71.4, 78.5) 91.1 (84.9, 97.3) <0.0005 
BMI (kg/m2) 25.6 (24.5, 26.7) 30.8 (29.0, 32.6) <0.0005 
WC (cm) 88 (84, 91) 105 (98, 107) <0.0005 
SBP (mmHg)  121 (118,  124) 145 (138, 150) <0.0005 
DBP (mmHg)  75 (73, 77) 88 (84, 92) <0.0005 
Fasting glucose (mmol/l)  4.9 (4.8, 5.0) 5.6 (5.2, 6.2) 0.003 
Triglycerides (mmol/l)  1.0 (0.8, 1.1) 1.7 (1.1, 1.9) 0.001 
HDL-C (mmol/l) 1.8 (1.6, 1.9) 1.5 (1.3, 1.9) 0.046 
Liver fat % (CH2/H2O)  1.7 (1.0, 2.4) 5.5 (3.6, 7.4) <0.0005 
BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; HDL-C, high density lipoprotein cholesterol. 
 
Table 4.2 The number of risk factors of metabolic syndrome (MetS) and liver fat in 
98 individuals. Classification column is listed as healthy top and MetS bottom. 
Risk factor Classification N (%) 
Waist circumference (cm)  
≤94M/81F 
>94M/80F 
65 (66%) 
33 (34%) 
Triglycerides; TG (mmol/l) 
≤1.7 
>1.7 
83 (85%) 
15 (15%) 
High density lipoprotein; HDL (mmol/l) 
≥1.03M/1.29F 
<1.03M/1.29F 
91 (93%) 
7 (8%) 
Systolic blood pressure; SBP (mmHg) 
≤130 
>130 
64 (65%) 
34 (35%) 
Diastolic blood pressure; DBP (mmHg) 
≤85 
>85 
74 (76%) 
24 (24%) 
Fasting glucose (mmol/l) 
≤5.6 
>5.6 
88 (90%) 
10 (10%) 
   M, male classification; F, female classification 
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4.3.2 Physical activity and cardiorespiratory fitness  
Physical activity and cardiorespiratory fitness data is summarised in Table 4.3. On 
average, individuals were taking 10939 steps/day (10213, 11665) and spent 1008 
min/day (979, 1037)   sedentary; V̇O2 peak average was 32.9 ml/kg/min (31.1, 34.6).  
Table 4.3 Summary of physical activity and cardiorespiratory fitness data. 
 Mean (95% CI) 
Average daily steps (steps/day) 10939 (10213, 11665) 
Daily sedentary time (min) 1008 (979, 1037) 
Daily light time (min) 241 (223, 259) 
Daily moderate time (min) 124 (110, 139) 
Daily vigorous time (min) 19 (14, 24) 
Daily lying time (min) 486 (469, 503) 
Daily sleep duration (min) 403 (389, 417) 
Daily metabolic equivalents (METS) 1.6 (1.5, 1.7) 
V̇O2 peak (ml/kg/min) 32.9 (31.1, 34.6) 
    
4.3.3 Liver fat  
Univariable linear regression analysis revealed several factors associated with physical 
activity that were predictors of liver fat (Table 4.3). For every increase of 1,000 daily 
steps, liver fat decreased by 0.95% whereas for every hour increase in daily sedentary 
time liver fat increased by 1.09%. Greater amounts of daily vigorous activity, METS 
and V̇O2 peak were significantly associated with lower levels of liver fat. In the 
multivariable analysis, three of the factors associated with physical activity remained 
statistically significant predictors of liver fat percentage (Figure 4.1). Greater amounts 
of daily sedentary time is associated with greater amounts of liver fat, whilst higher 
overall daily METS and V̇O2 peak are associated with lower levels of liver fat.
85 
 
Table 4.2 Univariate and multivariate regression for liver fat. 
Data was transformed and analysed using 1og10; data presented here is back transformed to original units. BMI, body mass index; METS, metabolic 
equivalents; V̇O2 peak, cardiorespiratory fitness; MVPA, moderate-vigorous physical activity.  
 
 
 
 
 Univariate Multivariate 
β coefficient 95% CI P β coefficient 95% CI P  
Age (years) 1.02 1.01, 1.06 <0.0005 1.00 1.00, 1.02 0.343 
BMI (kg/m2) 1.10 1.03, 1.24 <0.0005 1.01 0.97, 1.12 <0.0005 
Steps (1,000) -0.95 -0.86, -0.95 0.023 -0.97 -0.89, -0.97 0.103 
Sedentary time (hr) 1.09 1.08, 1.29 0.023 1.15 1.14, 1.50 0.036 
Vigorous activity (hr) -0.68 -0.32, -0.68 0.049 -0.99 -0.95, -1.00 0.237 
METS (0.1) -0.94 -0.84, -0.95 0.040 -0.48 -0.13, -0.56 0.012 
V̇O2 peak (ml/kg/min) -0.97 -0.92, -0.98 0.001 -0.87 -0.25, -1.50 0.007 
Light activity (hr) -0.90 -0.72, -0.91 0.077 
Moderate activity (hr) -0.95 -0.78, -1.04 0.478 
MVPA (hr) -0.94 -0.79, -1.00 0.301 
Lying time (hr) 1.03 0.95, 1.20 0.596 
Sleep duration (hr) 1.03 0.91, 1.22 0.741 
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Figure 4.1 Association of liver fat (log10) percentage (%) with A) daily average steps, B) sedentary time, C) light activity, D) moderate-
vigorous activity, E) metabolic equivalents (METS) and F) V̇O2 peak; P value represents multivariate regression analysis. 
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4.3.4 Whole body insulin sensitivity 
Greater daily average steps, METS and V̇O2 peak were significantly associated with 
greater whole body insulin sensitivity (Matsuda index) when exploring this data using 
univariable linear regression (Table 4.4). Additionally, univariable analysis also 
revealed that for every hour increase in daily sedentary time, Matsuda index would 
decrease by 0.93.  However, multivariable logistic regression analysis did not reveal 
any independent associations between physical activity/fitness and whole body insulin 
sensitivity. There was a modest correlation between liver fat and Matsuda index (R2= 
0.5; P<0.005) in this cohort. 
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Table 4.3 Univariate and multivariate regression for whole body insulin sensitivity (Matsuda index).  
Data was transformed and analysed using 1og10; data presented here is back transformed to original units. BMI, body mass index; METS, metabolic 
equivalents; V̇O2 peak, cardiorespiratory fitness; MVPA, moderate-vigorous physical activity.
 Univariate Multivariate 
β coefficient 95% CI P β coefficient 95% CI P  
Age (years) 1.00 0.99, 1.00 0.589 1.01 -1.00, 1.02 0.119 
BMI (kg/m2) -0.97 -0.92, -0.98 0.003 -0.98 -0.94, 0.99 0.151 
Steps (1,000) 1.04 1.03, 1.12 0.013 1.02 -1.01, 1.09 0.225 
Sedentary time (hr) -0.93 -0.83, -0.95 0.009 -0.94 -0.81, 0.98 0.248 
METS (0.1) 1.04 1.04, 1.12 0.045 -0.95 -0.84, 0.99 0.237 
V̇O2 peak (ml/kg/min) 1.02 1.01, 1.06 0.003 1.01 -1.01, 1.05 0.154 
Light activity (hr) 1.07 -1.05, 1.25 0.111 
Moderate activity (hr) 1.09 -1.08, 1.32 0.087 
Vigorous activity (hr) 1.18 -1.06, 1.85 0.234 
MVPA (hr) 1.07 -1.05, 1.24 0.105 
Lying time (hr) -0.94 -0.82, 0.97 0.158 
Sleep duration (hr) -0.97 -0.85, 1.05 0.582 
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4.3.5 Body mass index (BMI) 
Several factors were revealed from univariable linear regression analysis as significant 
predictors of BMI (Table 4.5). Average daily steps, vigorous activity, METS and V̇O2 
peak were significantly associated with BMI, such that, greater levels observed in these 
measures were inversely associated with BMI. For every hour increase in daily 
sedentary time BMI was predicted to increase by 1.0 kg/m2; whereas for every hour 
increase in daily light activity BMI was predicted to decrease by 1.7 kg/m2. 
Multivariable analysis revealed that sedentary time, light activity, METS and V̇O2 
peak were all independent predictors of BMI (Figure 4.2). However, daily average 
steps and vigorous activity were not. In this cohort, there was a modest correlation 
between BMI and liver fat (R2= 0.6; P<0.005) as well as a low negative correlation 
with BMI and Matsuda index (R2= -0.3; P=0.003). 
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Table 4.4 Univariate and multivariate regression for body mass index (BMI).   
BMI, body mass index; METS, metabolic equivalents; V̇O2 peak, cardiorespiratory fitness; MVPA, moderate-vigorous physical activity.  
 
 
 
 Univariate Multivariate 
β coefficient 95% CI P β coefficient 95% CI P  
Age (years) 0.14 0.07, 0.21 <0.0005 0.09 0.02, 0.16 0.013 
Steps (1,000) -0.50 -0.78, -0.22 0.001 -0.17 -0.45, 0.11 0.223 
Sedentary time (hr) 1.03 0.63, 1.43 <0.0005 1.70 0.56, 2.84 0.004 
Light activity (hr) -1.71 -2.36, -1.07 <0.0005 -2.20 -3.23, -1.18 <0.0005 
Vigorous activity (hr) -3.64 -6.11, -1.17 0.004 0.54 -3.15, 4.22 0.773 
METS (0.1) -0.81 -1.11, -0.51 <0.0005 -1.09 -2.01, -0.17 0.021 
V̇O2 peak (ml/kg/min) -0.32 -0.44, -0.21 <0.0005 -0.14 -0.28, 0.00 0.050 
Moderate activity (hr) -0.62 -1.52, 0.27 0.172 
MVPA (hr) -0.71 -1.43, 0.01 0.052 
Lying time (hr) 0.36 -0.38, 1.10 0.336 
Sleep duration (hr) 0.75 -0.16, 1.66 0.104 
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Figure 4.2 Association of body mass index (BMI) with A) daily average steps, B) sedentary time, C) light activity, D) moderate-vigorous activity, 
E) metabolic equivalents (METS) and F) V̇O2 peak; P value represents multivariate regression analysis.
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4.4 Discussion  
This study is the first to objectively monitor PA and sedentary behaviour with MRS 
derived quantification of liver fat in young to middle aged individuals. The data reveals 
that daily sedentary time is an independent predictor of liver fat percentage, such that 
a greater amount of daily sedentary time is associated with higher levels of liver fat.  
Sedentary time was also a significant predictor of BMI, as was daily light activity (1.5-
3 METS). Taken together, sedentary time, overall daily METS and V̇O2 peak were the 
most predominant predictors of liver fat and BMI. MVPA was not significantly 
associated with either liver fat or BMI. In this cohort, whole body insulin sensitivity 
was not independently predicted by physical activity domains or fitness. 
The strong inverse association with various types of PA and the prevalence of NAFLD 
has been recently reviewed (Qiu et al., 2017, Romero-Gómez et al., 2017, Zelber-Sagi 
et al., 2016). However, this study aimed to explore unresolved questions related to the 
physical behaviours associated with higher levels of liver fat. In a comparable study, 
Long et al., found that higher levels of PA were significantly associated with liver fat 
however sedentary time was not (Long et al., 2015). Such contradictory findings in a 
similar cohort (~27% fatty liver, 28 kg/m2 BMI) could be explained by mean sedentary 
time which was almost 3 hours greater than that of the current study. Moreover, liver 
fat was quantified by computed tomography (CT) therefore direct comparison is 
invalid. The majority of previous studies have examined the PA behaviours of those 
with and without NAFLD. This research approach does not determine whether because 
of low PA individuals have NAFLD or vice versa because of NAFLD individuals have 
low PA. Some authors have shown no association between liver fat and both PA and 
sedentary time (Keating et al., 2016) whereas others have concluded that PA and 
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sedentary time are independently associated with the prevalence of NAFLD 
(Hallsworth et al., 2015, Ryu et al., 2015). 
Historically, chronic disease prevention strategies have largely focused on MVPA (i.e. 
exercise). Interestingly, no association was observed between MVPA and the 
measured health outcomes (liver fat, BMI and insulin sensitivity) in the current study. 
Compliance with national PA guidelines (150 min of moderate activity per week) has 
been associated with the lowest odds of fatty liver previously (Long et al., 2015). 
Although the current study did not selectively recruit for active participants, the 
majority were meeting PA guidelines which may explain the lack of association. That 
being said, strong evidence shows greater levels of MVPA are positively associated 
with metabolic equivalents (METS) and cardiorespiratory fitness (V̇O2 peak) (Garber 
et al., 2011). The results here reveal METS and V̇O2 peak as independent predictors of 
liver fat and BMI. The importance of overall physical activity and its influence on 
these two health parameters cannot be disregarded. Recent research in a population-
based sample of adults shown that V̇O2 peak is strongly, inversely and independently 
related to the risk of liver fat (PÄLve et al., 2017). Importantly, and in agreement with 
the data presented here, the associations between V̇O2 peak and liver fat remained after 
adjustment for BMI; not all previous studies have similar findings (Minder et al., 2014, 
Church et al., 2006). 
BMI was investigated in the current study given its potential role in the development 
of liver fat and other cardiometabolic complications. The results demonstrate that less 
daily sedentary time and greater light activity, METS and V̇O2 peak was associated 
with reduced BMI. These data further reiterate a public health message that places 
emphasis on day to day activity. Irrespective of BMI, many studies have strongly 
indicated the importance of regional body fat distribution in the prevalence of NAFLD 
94 
 
(Kim et al., 2016, Park et al., 2008, van der Poorten et al., 2008). It is proposed that 
larger areas of visceral adipose tissue (VAT) are associated with increased risk of 
NAFLD whereas larger areas of subcutaneous adipose tissue (SAT) are associated 
with a reduced risk (Kim et al., 2016). Whilst our study design included the 
measurement of these fat depots, technical issues during a period of these 
investigations meant that VAT and SAT quantification was only available for 72 
individuals (Appendix 1 and 2 respectively) and as such, could not be included in 
overall analysis of liver fat due to differences in sample size. The abdominal location 
of VAT and its greater metabolic activity has been shown to have more adverse effects 
than SAT. Albeit controversial, Després has questioned whether increased VAT is a 
culprit of liver fat or merely a marker (Despres, 2012). Notably, liver fat, but not total 
body fat or VAT, has been identified as an independent predictor of insulin resistance 
(Linder et al., 2014).  
Insulin resistance plays a key role in the development of liver fat via several 
mechanisms including reduced skeletal muscle glucose uptake, impaired suppression 
of hepatic glucose production and increased circulating free fatty acids from adipose 
tissue. Although whole body insulin sensitivity was not predicted by physical activity 
domains or fitness in the current cohort, certain trends deserve discussion and potential 
further investigation. In a recent review (Bird and Hawley, 2016), studies involving 
PA confirm its efficacy in improving insulin sensitivity. A lifestyle that complies with 
the PA guidelines is associated with optimal insulin sensitivity. The failure here to 
observe an association in this cohort could be attributed again to the majority of 
participants being ‘recreationally active’ or further due to relatively ‘good’ insulin 
sensitivity. Future investigation in a larger cohort with a greater span of physical 
activity levels and/or glycaemic control may be beneficial.  
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It is recognised that breaks within sedentary time are also independently associated 
with metabolic risk (Healy et al., 2008). Whilst the results of the current study 
demonstrate that overall sedentary time needs to be considered independently of 
physical activity, future research should investigate sedentary behaviour patterns. A 
low sample size is a limitation of this research, as is the cross-sectional approach which 
removes the ability to assign causality. It is also important to note that the assocations 
observed with PA domains and liver fat were very week, absolute data is shown in 
Appendix, Table 8.1; a larger cohort of study is required. Recent prospective studies 
confirm the relationship between PA and NAFLD (Gerage et al., 2017, Kwak et al., 
2017). However, prospective research must also employ such objective measures of 
PA to provide robust evidence.  It is worth noting that even in adults meeting PA 
guidelines, a large amount of sedentary time increases the risk of becoming overweight 
or developing metabolic disorders (Levine et al., 2005). Targeting a change in 
sedentary behaviour can be considered as either an additional to physical activity 
guidelines or as a minimal requirement to improve health. In a quest to develop 
prevention strategies that are adoptable in a population reluctant to move more, 
advancing the knowledge within this field is paramount. 
In conclusion, a greater amount of sedentary time independently predicted a greater 
amount of liver fat. MVPA did not significantly influence liver fat, BMI and insulin 
sensitivity in this recreationally active cohort. Light activity and sedentary behaviour 
were associated with BMI with overall daily METS and V̇O2 peak associated with both 
liver fat and BMI. An increasing amount of evidence suggests a role of sedentary time 
in the development of, or predisposition towards NAFLD, independent of physical 
activity/exercise. Targeting sedentary time in addition to physical activity and exercise 
recommendations seems vital. Public health messages need to emphasise the 
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independent importance of reduced sedentary time in even healthy, and somewhat 
physically active individuals.  As the epidemic of obesity, T2D and NAFLD continues 
to grow, ‘behavioural change’ strategies at the population-level are needed.  
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5.1 Introduction  
Epidemiological evidence indicates that physical inactivity and sedentary behaviour 
are major causal factors in the development of obesity, insulin resistance and type 2 
diabetes (T2D) (Lee et al., 2012, Henson et al., 2013). However, such data provides 
no mechanistic insight into these pathophysiological changes. One plausible paradigm 
suggests that physical inactivity causes a reduction in skeletal muscle insulin 
sensitivity, contributing to a repartitioning of energy substrates into storage, increasing 
central fat accumulation and ectopic storage within the liver and other organs, causing 
further insulin resistance (Jornayvaz et al., 2010, Rabol et al., 2011, Rector and 
Thyfault, 2011, Petersen et al., 2007, DeFronzo and Tripathy, 2009). As peripheral 
insulin resistance progresses, continued ectopic fat accumulation within the liver and 
pancreas precipitates development of metabolic syndrome, a progressive decline in ß-
cell function and ultimately T2D (Tan and Vidal-Puig, 2008).  
To date, mechanistic human studies pertaining to inactivity have used extreme 
experimental models including bed rest (Alibegovic et al., 2010), limb immobilisation   
(Abadi et al., 2009) and cessation of exercise in trained volunteers (King et al., 1988). 
These models are not physiologically representative of habitual activity levels in free-
living individuals, and should be interpreted cautiously. More recently, an alternative 
experimental model has been developed in which active (~10,000 steps/day), healthy 
volunteers, who do not participate in regular exercise, transition to an inactive lifestyle 
(reducing up to ~1,500 steps/day) for brief periods (~14 days). This approach reflects 
societal changes in physical activity levels (i.e. reduced physical activity and more 
sedentary time) (Church et al., 2011, Althoff et al., 2017). Step-reduction models have 
demonstrated that physical inactivity results in detrimental physiological changes 
including reduced cardiorespiratory fitness, accumulation of central fat, loss of skeletal 
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muscle mass with associated anabolic resistance, and reductions in peripheral insulin 
sensitivity (Krogh-Madsen et al., 2010, Olsen et al., 2008, Knudsen et al., 2012, Breen 
et al., 2013). Importantly, such research provides a mechanistic basis for the 
consequences of increased sedentary behaviour and aids understanding of the 
development of metabolic disease. 
First-degree relatives (FDR) of individuals with T2D have a 3-fold increased risk of 
developing the disease themselves compared to those without a family history (Meigs 
et al., 2000); this risk can further be increased with low physical activity levels (Hu et 
al., 1999). No previous studies have employed a step-reduction protocol to examine 
whether individuals genetically predisposed to T2D are more susceptible to the 
adverse metabolic consequences of an inactive lifestyle, compared to those who are 
not. Given that group-specific physical activity guidelines have been proposed for 
other high-risk groups (e.g. South Asians) and that the exercise dose-response curve 
clearly differs between populations (Celis-Morales et al., 2013), this is a very pertinent 
research question. Furthermore, only one other study has investigated whether the 
detrimental effects of step-reduction are reversed when habitual physical activity is 
resumed (Knudsen et al., 2012).  
The primary aim of this study is to investigate the consequences of short-term physical 
inactivity (>80% step-reduction) in FDR of T2D versus healthy controls (CON), 
hypothesising that FDR will have greater adverse changes as a direct result of reduced 
activity. The secondary aim of this study is to investigate the recovery responses when 
activity levels are resumed, hypothesising an impaired recovery in those with FDR. 
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5.2 Methods 
5.2.1 Screening and eligibility  
A two tiered screening process was employed. As summarised in Figure 5.1, tier one 
screened for eligibility and tier two screened for intervention. In the first instance, 
individuals who expressed their interest in the study were screened for eligibility by 
questionnaire over the telephone or email. This process required individuals to detail 
their activity levels which excluded 64 individuals who were doing >2 hours of 
structured exercise per week. The feasibility of step-reduction and commitment time 
required for assessment visits were discussed in depth with each person individually 
to ensure full understanding and compliance to protocol, 18 individuals declared they 
were ‘unable to commit’ due to occupation or caring commitments.  Medical 
exemptions included unsuitability for magnetic resonance (MR) and prescribed 
medications, excluding 9 individuals.  
Of those that were screened for intervention, which included physical activity 
monitoring (outlined in detail below), 13 individuals over estimated their daily step 
count and were therefore excluded (<10,000 steps/day). Following commencement of 
the study, there was a 10% drop out rate i.e. withdrawals which were due to participant 
circumstance, namely occupational commitments. The term completed intervention 
refers to attendance to all assessment visits, complete adherence to step-reduction and 
monitoring of physical activity throughout, analysis was per protocol. One FDR 
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participant was excluded for insufficient wear time of the activity monitor and one 
CON participant for absence of significant step-reduction. 
Figure 5.1 Screening, recruitment, retention and completion study numbers. 
 
Embedded in the screening process was instruction of how to feasibly achieve ~1,500 
steps per day. This had to be well thought out, discussed and planned prior to the 
commencement of the step-reduction period and dates meticulously planned around 
the participants work and social life. Bespoke advice was given to each participant 
including suggestions such as; public transport, car sharing, taxis, taking the elevator 
instead of stairs, online shopping, working from home as well as spending more time 
doing  sedentary hobbies (e.g. television viewing, creative writing, crafts).  
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5.2.2 Participants 
All participants were habitually physically active with no history of regular structured 
exercise or highly physical employment. Individuals who had any cardiovascular, 
respiratory, kidney, liver and/or endocrine complications were excluded as were 
smokers and those who consumed >14 units of alcohol per week were excluded. A 
FDR is classed as a parent, sibling or child of somebody who has received a clinical 
diagnosis of T2D. Control participants (CON) confirmed no FDR with T2D. 
5.2.3 Physical activity screening and habitual dietary assessments 
Physical activity (PA) screening was conducted in a free-living environment and 
consisted of monitoring from midnight to midnight on 4 consecutive days, including 
one weekend day. Eligibility requirements were >10,000 steps per day. During this 
period physical activity was monitored using a SenseWear armband (Model MF-SW, 
BodyMedia, UK). The participants were instructed to wear the activity monitor at all 
possible times, inclusion criteria was >90% wear time which was monitored using 
SenseWear Professional software (version 8.0). The data collected included average 
daily step count, total energy expenditure and time spent in domains of activity 
including: sleep, sedentary (<1.5 METS), light (1.5-3 METS), moderate (3-6 METS), 
vigorous (6-9 METS) and very vigorous (>9 METS) activity. Dietary records were 
collected during the same 4 days screening period. Participants were instructed to 
maintain their usual habitual behaviours throughout the screening period.  
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5.2.4 Research design 
Following PA screening, participants underwent their initial assessment visits before 
being instructed to reduce their activity to ~1500 steps for a 14 day period after which 
the assessments were repeated (Figure 5.2). Normal habitual activity was then resumed 
for 14 days before participants underwent their final assessment visit. Screening and 
resumption of normal activity were blinded to the participant as the armband does not 
have a display or provide any output of information. If participants successfully met 
the inclusion criteria they were issued with a display device which was synchronised 
with the physical activity monitor armband to allow participants to adequately monitor 
and reduce their steps, during step-reduction. Dietary records were obtained 4 days 
prior to an assessment visit.  
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Figure 5.2 Schematic of study design for step-reduction intervention. Complete objective assessment of physical activity throughout 
screening (baseline), step-reduction and resumption of normal activity. Y axis represents daily average step and X axis study day. 
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5.2.5 Assessment measures  
Assessment visits were conducted on 3 separate occasions, this included baseline 
(following 4 day screening), step-reduction (following 14 day reduced physical 
activity) and resuming activity (following 14 day resumption of normal activity) 
(Figure 5.2). At each time point there were two visits. Visit one included body 
composition measures at LiMRIC and visit two metabolic measures at University 
Hospital Aintree.  For details of the experimental procedures please refer to Chapter 
2, General Methods. Participants were required to fast overnight for >8 hours, abstain 
from alcohol and caffeine 24 hours and refrain from exercise 48 hours prior to 
experimental appointments. All participants were studied at the same time of day to 
account for circadian variation (Jones et al., 2010).  
5.2.6 Sample size calculation  
The primary outcome variable for this study was the change in insulin sensitivity 
between the two groups. Based upon previous data (Knudsen et al., 2012) and using 
MINITAB 16; a sample size of 50, SD=1.1 (25 in each group) was calculated using an 
interpendant t-test to have ≥80% power to detect a standardized mean difference of 
0.89 for insulin sensitivity using Matsuda index with 5% significance level, assuming 
a 20% drop out rate (20 completed participants per group). 
5.2.7 Statistical analysis  
All data were explored for distribution using visual inspection of frequency 
distribution, and logarithmically transformed using 1og10 or logsqr, where appropriate. 
Baseline analysis was performed on clinical characteristics of first-degree relatives 
(FDR) compared with control (CON) individuals using independent t-tests. The 
coefficient of determination (R2) was calculated from Pearson correlation coefficients 
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to evaluate collinearity between variables. Data were then analysed whilst controlling 
for baseline differences as model covariates. The groups’ responses to the intervention 
were compared by calculating delta (Δ) change and analysed using a two factor 
between-groups (group x time) analysis of covariance (ANCOVA) with respective 
baseline data entered as a covariate. The term intervention refers to step-reduction and 
resumption of normal activity. Statistically significant interactions were assessed using 
the least significant difference (LSD) approach to multiple pairwise comparisons. 
Paired sample t-tests were used to assess for any differences between baseline and 
resumption of activity. The alpha level of statistical significance was set at P<0.05. 
Data are presented as mean (95% confidence intervals [CI]), unless stated otherwise 
and exact P values are cited (values of P of “0.000” provided by the statistics package 
are reported as “<0.0005”). Logarithmically transformed data were back transformed 
to original units and presented in the text as mean (95% CI). Statistical analysis was 
performed using Statistical Package for Social Sciences (SPSS) for Windows (Version 
24.0, SPSS Inc., Chicago, IL, USA) statistic software package. 
5.3 Results 
5.3.1 Participant demographics 
A total of forty-five participants were included in this study, 28 females and 17 males. 
FDR included 10 female, and 6 male, CON included 18 female, and 11 male; 
percentage splits were 62% female and 38% male for each. Mean age of all the 
participants was 36 ± 14 years; FDR were on average 7 (3, 14) years older than CON 
(Table 5.1). An average daily step count >10,000 was required to be included in the 
study. FDR demonstrated a mean daily step count of 12524 steps/day (11214, 13835), 
CON had a mean daily step count of 13036 steps/day (12035, 14037); there was no 
significant difference between groups (P=0.391).  
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5.3.2 Baseline characteristics 
The baseline characteristics of FDR and CON groups are listed in Table 5.1; FDR had 
significantly greater values for BMI, overall body mass, waist circumference and hip 
circumference (P<0.05). Fasting insulin and HOMA-IR were significantly higher in 
CON. All other variables were not statistically significant. BMI had evidence of 
collinearity with body mass (R2=0.645), waist circumference (R2=0.703) and hip 
circumference (R2=0.719). As a representative measure of these differences within 
body composition, BMI was selected as a valid covariate within the ANCOVA model. 
Fasting insulin and HOMA-IR had high evidence of collinearity (R2 =0.943), HOMA-
IR was selected as a valid covariate and fasting insulin was removed from the analyses. 
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Table 5.1 First-degree relatives (FDR, n=16) and control (CON, n=29) subject 
characteristics at baseline, displaying mean (95% confidence interval) and statistical 
significance. 
 FDR CON  P value 
Clinical characteristics 
Age (years) 40 (31, 48) 33 (28, 39) 0.166 
Body mass (kg) 79.3 (72.2, 86.4) 68.9 (65.1, 72.6) 0.011 
BMI (kg/m2) 27 (24, 29) 24 (23, 25) 0.018 
Waist circumference (cm) ¥ 93 (86, 100) 84 (80, 88) 0.029 
Hip circumference (cm) ¥ 103 (97, 108) 95 (92, 98) 0.015 
Waist: hip ratio 0.91 (0.86, 0.95) 0.89 (0.86, 0.92) 0.052 
SBP (mmHg) 122  (114, 129) 121  (116, 127) 0.932 
DBP (mmHg) 74  (70, 78) 76  (72, 80) 0.438 
Physical fitness and activity 
V̇O2 (l/min) 2.5  (2.2, 2.8) 2.4 (2.2, 2.6) 0.676 
V̇O2 peak (ml/kg/min) 32.1 (28.5, 35.8) 35.3 (32.9, 37.9) 0.136 
V̇O2 peak lean (ml/kg/min) 50.1 (47.1, 53.1) 52.6 (50.0, 55.3)  0.189 
Energy expenditure (kJ/day)  12251 (11019, 13483) 11383 (10189, 12577) 0.408 
Average steps (steps/day) 12524 (11214, 13835) 13036 (12035, 14037) 0.391 
Daily sedentary time (min) 1021 (948, 1093) 989 (940, 1038) 0.498 
Daily light activity  (min) 231 (184, 280) 240 (210, 270) 0.650 
Daily moderate activity (min) 130 (102, 154) 139 (114, 164) 0.306 
Daily vigorous activity (min) 21 (3, 38) 24 (12, 37) 0.550 
Lipid profile 
Cholesterol (mmol/l) 5.1 (4.5, 5.7) 4.9 (4.6, 5.2) 0.681 
Triglycerides (mmol/l) 1.0 (0.7, 1.2) 1.0 (0.8, 1.2) 0.524 
HDL (mmol/l)  1.8 (1.5, 2.2) 1.8 (1.6, 2.0) 0.907 
LDL (mmol/l) 2.8 (2.2, 3.4) 2.6 (2.3, 2.9) 0.475 
Cholesterol: HDL ratio 3 (2, 4) 3 (2, 3) 0.400 
109 
 
Glucose regulation 
Fasting glucose (mmol/l) 5.0  (4.6, 5.4) 5.0 (4.7, 5.2)  0.994 
Fasting insulin (µlU/ml) ¥ 12  (9, 15) 20 (15, 24) 0.002 
HOMA-IR ¥ 2.8 (2.2, 3.4) 4.3 (3.3, 5.2) 0.003 
Glucose AUC (mmol/l) 780 (652, 947) 799 (729, 870) 0.928 
Insulin AUC (µlU/ml) 8261 (5669, 10652) 9192 (7911, 10473) 0.468 
Whole body IS (Matsuda index) 4.1 (3.0, 5.3) 3.2 (2.3, 4.0) 0.155 
Hepatic-IR index (HIRI) 33.4 (27.5, 39.1) 40.5 (36.3, 44.7) 0.058 
Muscle-IS index (MISI) 0.07 (0.03, 0.10) 0.06 (0.05, 0.08)  0.749  
Body composition  
Total body fat (%) 33 (26, 40) 30 (27, 33) 0.279 
Android fat (%) 36 (27, 45) 30 (26, 35) 0.134 
Gynoid fat (%) 35 (27, 43) 34  (30, 37) 0.581 
Total lean mass (kg) 49.5 (44.0, 55.0) 46.0 (42.5, 49.6) 0.150 
Liver IHCL % (CH2/H2O) ¥ 3.0 (0.6, 5.4) 0.7 (0.4 1.1) 0.064 
Muscle IMCL % (CH2/creatine) 9.1 (5.8, 12.5) 6.4 (5.4, 7.4) 0.109 
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
V̇O2, maximal oxygen uptake; HDL, high density lipoprotein; LDL, low density 
lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; HIRI, 
hepatic insulin resistance index; MISI, muscle insulin sensitivity index; IHCL, 
intrahepatocellular lipid; IMCL, intramyocellular lipid. ¥ variables analysed following 
logarithmic transformation.  
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5.3.3 Physical activity  
The intervention induced significant changes in all activity measures (Figure 5.3). 
During the step-reduction period, average daily step count decreased by 10435 
steps/day (10810, 10060; P<0.0005), a reduction of 81%. In parallel, sedentary time 
increased by an average of 130 min/day (92, 168; P<0.0005) and total energy 
expenditure (TEE) decreased by an average of 2697 kJ/day (3008, 2385; P<0.0005). 
All activity >1.5 METS (i.e. light, moderate and vigorous) decreased during the step-
reduction period (all P<0.0005). There were no statistical differences between the 
groups in average daily step count, TEE, sedentary, light and moderate activity at any 
of the time points (P>0.05). Vigorous activity was significantly higher in CON 
(P=0.001); when explored, the group difference was not present at step-reduction 
(P=0.988) but rather at resuming activity (P=0.006). CON increased their vigorous 
activity during resumption of activity to a greater extent than FDR (Figure 5.3F). There 
were no significant differences in any of the physical activity measures between 
baseline and following resumption of activity (P>0.05). 
5.3.4 Dietary analysis  
Total energy consumption did not change throughout (P=0.330) and there was no 
difference between groups (P=0.372). Mean ±SD macronutrient percentages were 
56±15% carbohydrate, 24±10% protein, and 20±9% fat, these did not change 
throughout (P=0.235, P=0.268, P=0.924 respectively) and there was no difference 
between groups (P=0.660, P=0.179, P=0.177 respectively).
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Figure 5.3 Physical activity data first-degree relatives (FDR) and controls (CON) at baseline, following step-reduction and resuming activity 
including A) daily average step count, B) total energy expenditure, C) daily sedentary time (<1.5 METS), D) daily light activity (1.5-3 METS), E) 
daily moderate activity (3-6 METS) and F) daily vigorous activity (>6 METS); mean (SD), *P<0.05 main effect of time; **P<0.05 statistical 
difference between groups. 
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In the most part, the results presented herein are those observed in the entire sample 
(pooled FDR and CON groups). Where statistical differences occur between the 
groups or there is a significant interaction effect, it is explicitly noted.  
5.3.5 Anthropometrics and blood pressure 
Body mass, BMI and waist to hip ratio did not change in either group (P=0.611, 
P=0.553 and P=0.385 respectively). Pooled waist and hip circumference measures 
increased by 0.7 cm (0.4, 1.0) and 0.4 cm (0.1, 0.7) respectively (P<0.0005) after step-
reduction. Systolic blood pressure (SBP) increased by 4 mmHg (0, 8; P=0.037) 
following step-reduction, diastolic blood pressure (DBP) remained unchanged 
(P=0.982). There were no between group differences in any of the clinical 
characteristic changes.  
5.3.6 Biochemical measures 
Fasting glucose and insulin  
Fasting glucose was not significantly altered by the intervention, however, fasting 
insulin increased following step-reduction and decreased following resumption of 
habitual activity but to a similar extent in both groups (P=0.016). For fasting insulin 
changes, FDR showed augmented changes (P=0.046) while CON was not statistically 
different (P=0.278) (Table 5.2).  
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Table 5.2 Data of first-degree relatives (FDR) and controls (CON) following step-reduction and resuming activity; delta (∆) change values  SD; 
between-group difference (95% CI); p value for main group difference; [p value for pooled effect of time]. 
 
FDR CON Between-group difference 
p value  
Group [Time] ∆ Step-
reduction 
∆ Resuming 
activity 
∆ Step-
reduction 
∆ Resuming 
activity 
Step-reduction Resuming 
Clinical characteristics 
Body mass (kg) 
-0.1  1.0 -0.1  1.2 0.1  1.0 0.3  1.2 
-0.2 (-0.8, 0.5) -0.4 (-1.2, 0.4) 
0.241 [0.611] 
BMI (kg/m2) 
0  0.3 0  0.4 0  0.3 0  0.4 
0 (-0.3, 0.2) 0 (-0.4, 0.2) 
0.369 [0.553] 
WC (cm) ¥ 
0.6  1.0 -0.3  0.9 0.7  1.0 -0.4  0.8 
-0.1 (-0.8, 0.6) 0.1 (-0.5, 0.7) 
0.934 [<0.005] 
HC (cm) ¥ 
0.3  0.5 -0.3  0.6 0.1  0.5 -0.1  0.6 
0.2 (-0.2, 0.5) -0.2 (-0.7, 0.2) 
0.670 [<0.005] 
SBP (mmHg) 
-1  9 -3  8 2  8 -4  8 -2 (-8, 4) 1 (-4, 7) 0.654 [0.037] 
DBP (mmHg) 
-1  8 -2  9 -1  8 -1  8 1 (-5, 6) -1 (-7, 5) 0.846 [0.982] 
Glucose metabolism  
Fasting glucose (mmol/l) 
-0.1  0.5 0.1  0.4 -0.1  0.5 -0.1  0.4 
0.1 (-0.3, 0.3) 0.2 (-0.1, 0.5) 
0.171 [0.294] 
Fasting insulin (pmol/l) ¥ 
34  9 -35  11 17  8 -11  11 
18 (-24, 59) -25 (-79, 30) 
0.669 [0.016] 
HOMA-IR ¥ 
1.1  2.1 -1.1  2.6 0.4  2.1 -0.4  2.6 
0.7 (-0.7, 2.1) -0.7 (-2.5, 1.0) 
0.911 [0.027] 
Whole body IS (Matsuda) 
-0.7  1.2 0.3  2.3 -0.9  1.2 1.3  2.2 
0.1 (-0.7, 1.0) -1.1 (-2.7, 0.5) 
0.254 [<0.005] 
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BMI, body mass index; WC, waist circumference; HC hip circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; V̇O2, 
maximal oxygen uptake; HDL, high density lipoprotein; LDL, low density lipoprotein; HOMA-IR, homeostatic model assessment of insulin 
resistance. ¥ Variables analysed following logarithmic transformation.  
NB. Absolute values of each variable are presented to the nearest accuracy of measurement. Where ∆ change values do not demonstrate a 
difference, data are presented with one decimal place (dp), if by laws of rounding one dp does not suffice that value only is increased to 2 dp. 
 
Lipid profile  
Cholesterol (mmol/l) 0.2  0.8 -0.2  0.9 0.2  0.8 -0.3  0.8 -0.1 (-0.6, 0.4) 0.9 (-0.5, 0.7) 
0.962 [0.041] 
HDL (mmol/l) -0.1  0.3 0  0.4 0  0.3 0  0.4 0 (-0.2, 0.2) 0 (-0.3, 0.2) 
0.495 [0.641] 
LDL (mmol/l) 0.8  0.5 -0.1  0.6 1.2  0.5 -0.2  0.5 -0.2 (-0.5, 0.2) 0.2 (-0.2, 0.5) 
0.930 [0.013] 
Body composition 
Total lean mass (kg) -0.6  0.9 0.4  1.2 -0.1  0.9 0.4  1.1 -0.4 (-1.0, 0.2) 0.2 (-0.6, 1.0) 
0.598 [0.005] 
Leg lean mass (kg) -0.1  0.4 0.2  0.5 -0.2  0.4 0.2  0.5 0.2 (-0.1, 0.4) -0.1 (-0.4, 0.3) 
0.589 [0.004] 
Arm lean mass (kg) 0.1  0.2 0.1  0.2 -0.1  0.2 0.1  0.2 0.1 (-0.1, 0.2) 0.1 (-0.1, 0.2) 
0.607 [0.502] 
Cardio-respiratory fitness 
V̇O2 (l/min) 
-0.2  0.3 0.3  0.4 -0.1  0.3 0.1  0.4 -0.1 (-0.3, 0,1) 0.2 (-0.1, 0.5) 0.376 [0.002] 
V̇O2 peak (ml.min-1.kg-1) 
-3.0  4.8 3.6  5.6 -1.4  4.6 0.9  5.5 -1.6 (-4.8, 1.6) 2.7 (-1.1, 6.7) 0.370 [0.002] 
V̇O2 lean (ml.min-1.kg-1) 
-4.0  7.3 4.9  8.5 -1.9  6.9 1.1  8.1 -2.2 (-7.1, 2.7) 3.9 (-1.8, 9.6) 0.394 [0.006] 
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Lipid profile 
Total cholesterol significantly increased by 0.5 mmol/l (0.1, 0.9; p=0.041) following 
step reduction: HDL cholesterol remained unchanged (P=0.641) while LDL 
significantly increased by 0.3 mmol/l (0.1, 0.6; P=0.013). Triacylglycerol pooled 
outcomes also increased following step-reduction by 0.5 mmol/l (0.2, 0.7; P=0.002) 
but a between-group difference was present whereby FDR had a 0.3 mmol/l greater 
change (0.1, 0.6; P=0.044) (Figure 5.4). 
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Figure 5.4 Lipid blood data first-degree relatives (FDR) and controls (CON) at baseline, following step-reduction and resuming 
activity including A) cholesterol, B) triglycerides, C) high density lipoprotein (HDL) cholesterol D) low density lipoprotein 
(LDL) cholesterol; mean (SD), *P<0.05 main effect of time; **P<0.05 statistical difference between groups. 
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5.3.7 Cardiorespiratory fitness 
The period of reduced physical activity significantly lowered cardio-respiratory fitness 
across the study population, whichever way this was expressed (absolute, relative to 
body weight or lean body mass): V̇O2 by 0.3 l/min (0.5, 1.0; P=0.002), V̇O2 peak per 
kg of body mass by 2.2 ml/kg/min (0.9, 3.6; P=0.002) and V̇O2 peak per kg of lean 
body mass by 2.9 ml/kg/min (0.9, 5.0; P=0.006) (Figure 5.5A) with no between-group 
differences for any of these measures. 
5.3.8 Body composition  
Lean body mass  
Total lean mass decreased by 0.3 kg (0.1, 0.6; P=0.005), as did total leg lean mass by 
0.2 kg (0.1, 0.3; P=0.004), but there was no significant change in arm lean mass 
(P=0.502).  
Regional fat mass  
Step-reduction induced similar changes in both groups total body fat which increased 
by 0.9% (0.6, 1.3; P<0.0005) and android fat which increased by 1.7% (1.1, 2.3; 
P<0.0005). In the two groups combined, gynoid fat increased by 0.6% (0.3, 0.8; 
P=0.001). However, a between-group difference was found whereby FDR 
accumulated 1.5% more android fat (0.4, 2.6; P=0.008) following step-reduction 
(Figure 5.6B).  
Liver fat  
IHCL increased following the period of reduced activity by 0.7 % CH2/H2O (0.2, 1.2; 
P=0.001). There were no statistically significant differences between groups in liver 
IHCL responses to the intervention, although a main effect for group approached 
statistical significance (P=0.066), FDR showing a trend for greater changes in IHCL 
compared to CON.  
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Skeletal muscle fat  
Muscle IMCL increased 1.0 % CH2/creatine (-0.3, 2.3) after the step-reduction phase 
but this did not reach statistical significance (P=0.094). 
Within-group comparisons Several within-group responses were different in terms 
of reaching statistical significance. All measures of cardio-respiratory fitness 
(absolute, relative to body weight and relative to lean body) were significant in FDR 
but not CON. As was fasting insulin and free-fatty acid AUC.
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Figure 5.5 Cardiorespiratory fitness and regional lean mass delta change (∆) in first-degree relatives (FDR) and controls (CON) 
following step-reduction and resuming activity; A) maximal oxygen uptake (V̇O2 peak), B) total lean mass, C) leg lean mass 
and D) arm lean mass; mean (SD), *P<0.05 main effect of time; **P<0.05 statistical difference between groups. 
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Figure 5.6 Regional and liver fat delta change (∆) responses of first-degree relatives (FDR) and controls (CON) following step-reduction 
and resuming activity; A) total body fat, B) android fat, C) gynoid fat, D) waist circumference, E) liver intrahepatocellular lipid (IHCL) and 
F) muscle intramyocellular lipid (IMCL); mean (SD), *P<0.05 main effect of time; **P<0.05 statistical difference between groups. 
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5.3.9 Multi-organ insulin sensitivity  
Whole body insulin sensitivity  
In both groups, the primary outcome measure of whole body insulin sensitivity 
(Matsuda index) significantly declined following step-reduction (P<0.0005) which 
was accompanied by a significant increase in glucose AUC (P=0.025) and insulin 
AUC (P<0.0005). However, no between-group differences in these measures were 
observed (Figure 5.7D).  
Skeletal muscle insulin sensitivity  
Muscle insulin sensitivity was significantly reduced following step-reduction 
(P<0.0005). Overall, there was a significant between-group difference of 0.015 (0.006, 
0.023; P=0.001), FDR displaying lower levels of muscle insulin sensitivity. Following 
resumption of activity there was a significant difference of 0.023 (0.003, 0.042; 
P=0.023) between the two groups, FDR displaying lower muscle insulin sensitivity 
(Figure 5.7D). 
Hepatic insulin resistance  
The intervention had no significant effect on hepatic-IR in either group (P=0.060) but 
HIRI was on average 3.8 greater in FDR across the intervention (1.7, 6.4; P=0.007) 
(Figure 5.7F) 
Adipose tissue insulin resistance  
The intervention had an effect on free fatty acid AUC which was borderline significant 
(P=0.050) (Figure 5.7C).
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Figure 5.7 Metabolic responses of first-degree relatives (FDR) and controls (CON) at baseline, following step-reduction and resuming activity. Derived 
from oral glucose tolerance test (OGTT) A) glucose AUC, B) insulin AUC, C) free fatty acid AUC, D) whole body insulin sensitivity (Matsuda index) 
E) muscle insulin sensitivity index (MISI) and F) hepatic insulin resistance index (HIRI); mean (SD), *P<0.05 main effect of time; **P<0.05 statistical 
difference between groups. 
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Figure 5.8 Time course data of oral glucose tolerance test (OGTT) in first-degree 
relatives (FDR) [left panels] and controls (CON) [right panels]; A) glucose, B) insulin, 
C) free fatty acids. Baseline represented as a solid black line (-), step-reduction as a 
dashed black line (--), resuming activity solid grey line (-). **P<0.05 statistical 
difference between groups.  
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5.3.10 Summary of significant changes induced by step-reduction  
Table 5.3 Summary of significant changes in response to changes in physical activity, 
detailed for increase or decrease in both groups combined and group differences 
between FDR and control. 
OGTT, oral glucose tolerance test; HOMA-IR, homeostatic model assessment of 
insulin resistance; AUC, area under curve. 
 
 
 
 
∆ Step-
reduction  
∆ Resuming 
activity 
Group 
difference 
Physical activity 
Average daily steps 
Daily sedentary time 
Daily light activity 
Daily moderate activity 
Daily vigorous activity  
↓ 
↑ 
↓ 
↓ 
↓ 
↑ 
↓ 
↑ 
↑ 
↑ 
- 
- 
- 
- 
Yes 
Skeletal muscle  
Cardiorespiratory fitness 
Total lean mass 
Leg lean mass 
↓ 
↓ 
↓ 
↑ 
↑ 
↑ 
- 
- 
- 
Fat deposition 
Total body fat 
Android fat 
Gynoid fat 
Waist circumference 
Liver fat 
↑ 
↑ 
↑ 
↑ 
↑ 
↓ 
↓ 
↓ 
↓ 
↓ 
- 
Yes 
- 
- 
- 
Fasting metabolic profile 
Insulin  
HOMA-IR 
Cholesterol 
Triglycerides 
LDL cholesterol 
↑ 
↑ 
↑ 
↑ 
↑ 
↓ 
↓ 
↓ 
↓ 
↓ 
- 
- 
- 
Yes 
- 
Post-prandial metabolism  (OGTT) 
Glucose AUC 
Insulin AUC 
Free fatty acid AUC 
Matsuda index 
Muscle insulin sensitivity  
↑ 
↑ 
↑ 
↑ 
↓ 
↓ 
↓ 
↓ 
↓ 
↑ 
- 
- 
- 
- 
Yes 
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5.4 Discussion  
The results of this study demonstrate that even short-term physical inactivity, resulting 
in a decline in cardiorespiratory fitness, leads to unfavourable changes in body 
composition with reduced lower limb lean body mass, accretion of body fat, 
particularly centrally, and of liver fat. These changes are small, but large enough to be 
clinically significant and pose a serious health threat over a longer term (Thyfault and 
Krogh-Madsen, 2011). The metabolic sequelae of these changes include whole body 
insulin resistance and dyslipidaemia (increased triglycerides and LDL-cholesterol). 
Importantly, FDR+ve of type 2 diabetes demonstrated similar decompensation in 
whole body insulin sensitivity when compared with FDR-ve. However, some 
differences were noted: greater rise in plasma triacylglycerol, more android fat 
deposition and reduced skeletal muscle insulin sensitivity. Although these changes are 
reversible with resumption of normal physical activity, the pattern of the changes 
provides mechanistic insight into how chronic physical inactivity and increased 
sedentary behaviour contributes to development of metabolic syndrome, T2D, non-
alcoholic fatty liver disease and potentially cardiovascular disease (Wilmot et al., 
2012, Hallsworth et al., 2015). 
Previous research has focused on increasing habitual physical activity or structured 
exercise, yet little is known about the consequences of decreasing habitual physical 
activity. Validated measures of tissue-specific insulin sensitivity were used to 
demonstrate that inactivity resulted in decreased skeletal muscle insulin sensitivity. 
Skeletal muscle insulin sensitivity was significantly altered in both groups; notably the 
FDR participants failed to return muscle insulin sensitivity to baseline levels on 
resumption of habitual activity. While this may be an intrinsic defect, the FDR also 
had lower levels of vigorous activity on resumption of activity. As vigorous activity 
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induces greater uptake of skeletal muscle glucose (Cassidy et al., 2017), this could 
have influenced this between-group difference. Increased adipose tissue insulin 
resistance with lesser suppression of lipolysis and greater release of FFA during the 
OGTT was evidenced following inactivity. As was the expansion of the adipose tissue 
mass and small but important increases in liver fat. This peripheral insulin resistance 
and accumulation of liver fat was accompanied by a rise in plasma triglycerides, LDL-
cholesterol and an increase in blood pressure, all components of the metabolic 
syndrome. These data are consistent with the hypothesis proposed that physical 
inactivity results in a reduced metabolic demand of skeletal muscle leading to lower 
glucose uptake (by the development of peripheral insulin resistance) and repartitioning 
of energy substrates into storage in adipose tissue and in the liver by ‘overspill’, so 
that energy will be available when activity resumes (Rector and Thyfault, 2011). This 
paradigm is supported by measurements of post-prandial muscle and liver glycogen/ 
lipid (13C/1H magnetic resonance spectroscopy) and de novo lipogenesis (deuterated 
water, 2H20), which show that skeletal muscle insulin resistance promotes hepatic 
steatosis and hyperlipidaemia (Petersen et al., 2007, Jornayvaz et al., 2010). Moreover, 
this process can be reversed with exercise (Rabol et al., 2011). It is proposed that 
physical inactivity leads to central and hepatic fat accumulation, development of 
insulin resistance and emergence of components of the metabolic syndrome, including 
dyslipidaemia by a similar mechanism.  
This step-reduction study somewhat corroborates previous reports regarding the 
effects of physical inactivity on cardiorespiratory fitness and body composition 
(Krogh-Madsen et al., 2010, Olsen et al., 2008). The effects of inactivity are amplified 
when combined with overfeeding (Knudsen et al., 2012), leading to undesirable 
metabolic changes including impaired insulin sensitivity independent of changes in 
127 
 
body composition developing only 3 days into the intervention. The current findings 
represents a significant advance for several reasons. Previous step-reduction studies 
have been limited in sample size, the largest published studies being in 10 young males 
(Krogh-Madsen et al., 2010, Olsen et al., 2008); the present study is more 
representative of the general population, involving 45 individuals, both male and 
female, with a mean age of 36 years. Complete objective monitoring of physical 
activity throughout ensured that the baseline criteria of >10,000 steps/day was met and 
likewise ~1500 steps/day during inactivity, habitual activity was monitored during the 
final 14 days with no instruction or guidance. The time participants spent in domains 
of activity was objectively determined (categorised by METs) rather than using 
composite measures. Moreover, the participants involved in the study were 
comprehensively phenotyped, including all measures of metabolic syndrome, region-
specific distribution and quantification of lean muscle and adipose tissue by DXA, and 
liver fat quantified by 1H-MRS, a highly sensitive non-invasive method (Cuthbertson 
et al., 2014).  
The study is also the first to examine whether FDR of people with T2D are more 
susceptible to the detrimental effects of reduced physical activity compared to healthy 
controls. The findings do not suggest that FDR show greater adverse changes with 
inactivity compared with CON when we consider the effects on the primary outcome, 
whole body insulin sensitivity. However, there were differences in a subset of 
measures, with greater increases in triacylglycerol and android fat following step-
reduction and a more marked change in cardio-respiratory fitness. These differences 
may be important, not only associated with an increased risk for future development 
of insulin resistance and type 2 diabetes, but also long-term for cardiovascular disease 
and overall mortality (Pinnick et al., 2014). The presence of good metabolic health in 
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these relatively active individuals at baseline, the decline with increased sedentary time 
and restoration after resumption of habitual physical activity, all too some extent 
validate current physical activity recommendations. The findings reinforce the 
importance of meeting the physical activity recommendations for all participants. 
The limitations to the study design must be acknowledged.  The gold standard measure 
of insulin sensitivity is the hyperinsulinaemic euglycaemic clamp. Due to the 
participant burden of conducting serial clamps, whole body insulin sensitivity was 
assesses from an OGTT  using the Matsuda index which has been shown to correlate 
with hyperinsulinaemic euglycaemic clamp (Matsuda and DeFronzo, 1999). 
Calculations of hepatic insulin resistance and skeletal muscle insulin sensitivity have 
also been validated (Abdul-Ghani et al., 2007). The indices derived from OGTT are 
valid, repeatable and easily assessable measures of insulin sensitivity which is 
advantageous for direct comparison with follow-up studies. Future studies may wish 
to incorporate low and high-dose hyperinsulinaemic euglycaemic clamps to precisely 
measure hepatic and skeletal muscle insulin sensitivity and consider dynamic 
measurements of de novo lipogenesis and of very low density lipoproteins (VLDL) 
triglyceride kinetics to determine effects on liver fat and lipoprotein metabolism. These 
data provide a good rationale to determine the molecular and tissue-specific 
adaptations in skeletal muscle and subcutaneous adipose tissue in response to short-
term physical inactivity. Lastly, against what might be expected, the CON group had 
a higher fasting insulin and HOMA-IR than FDR. Whilst a lower total body lean mass 
in CON may account for this another possible explaination is due the variability in 
CON versus the smaller sample of  FDR. A larger cohort of matched (age, gender, 
body composition and sample number) study groups are needed.  
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In summary, by taking untrained individuals with a habitually active life style 
(>10,000 steps/day) and drastically reducing their step count, this study provides direct 
evidence of a number of unfavourable adaptations to body composition and 
cardiometabolic risks with increased sedentary behaviour. These changes reversed 
with resumption of habitual activity. The data suggests a mechanistic framework for 
understanding the deleterious cardiometabolic adaptations that occur with chronic 
physical inactivity and sedentary behaviour. Furthermore, FDR and CON are both 
susceptible to the risks of increased sedentary behaviour. The study findings reinforce 
the health benefits of meeting physical activity recommendations and emphasise the 
importance of avoiding prolonged sedentary behaviour.  
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Chapter 6.  
Synthesis of findings 
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Observational approaches were utilised to examine the role of habitual physical 
activity (PA) and sedentary behaviour on components of metabolic health and liver fat 
in obese and non-obese individuals. A greater amount of daily sedentary time was 
strongly associated with obesity and increased liver fat. These data demonstrated a 
sound basis for the subsequent interventional study, whereby metabolic disruptions 
caused by reduced physical activity (i.e. sedentary behaviour) were investigated in the 
context of type 2 diabetes (T2D) development. The primary aim of the intervention 
study was to determine if those with a first-degree relative (FDR) of a T2D patient was 
more susceptible to the detrimental effects of physical inactivity than healthy controls 
(CON). This investigation focused on how inter-organ cross-talk between the liver, 
skeletal muscle and adipose tissue mediates whole body metabolism. The major 
findings were: i) short-term physical inactivity induces altered body composition and 
metabolic decompensation in non-exercising adults that simply avoid physical activity 
(PA) for 14 days whilst maintaining their usual diet, ii) FDR of T2D demonstrated a 
greater increase in android fat and a greater rise in plasma triglycerides, and iii) 
resumption of habitual PA reversed all observed changes in both groups.  
6.1 Short-term physical inactivity induces altered body composition and 
metabolic decompensation in non-exercising adults that simply avoid 
PA for 14 days whilst maintaining their usual diet 
The pooled findings of FDR and CON participants clearly demonstrate the detrimental 
effects of sedentary behaviour on body composition; increased adipose tissue 
deposition and a reduction in skeletal muscle mass. The DXA derived results are 
generally consistent with the only two previous studies within this field (Krogh-
Madsen et al., 2010, Olsen et al., 2008). These authors also found that visceral adipose 
tissue (VAT) increased following physical inactivity which could potentially be a 
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marker of the observed increase of liver fat in the current investigation. It has however 
been questioned whether increased VAT is a culprit of liver fat or merely a marker 
(Despres, 2012). Notably, liver fat, but not total body fat or VAT, has been identified 
as an independent predictor of insulin resistance (Linder et al., 2014). The results of 
the current study together with previous investigations have shown that peripheral 
insulin sensitivity is altered following short-term physical inactivity but significant 
alterations in hepatic insulin resistance only present when 14 days of physical 
inactivity are coupled with overfeeding (Knudsen et al., 2012), suggesting that changes 
in peripheral insulin sensitivity precede hepatic. The outcomes of these data clearly 
demonstrate that physical inactivity induces central adiposity and insulin resistance, 
which is known to play a causal role in T2D (Hu et al., 2004). These results indicate 
that skeletal muscle was the likely cause of reduced insulin action. Identifying how 
these changes arise in FDR of T2D has important clinical implications for 
understanding a ‘double-edged sword’ (genetic predisposition and physical inactivity) 
in the development of the disease and its associated cardiometabolic complications.  
6.2 FDR of T2D demonstrated a greater increase in android fat and a 
greater rise in plasma triglycerides 
The effects of physical inactivity, by reduced ambulatory activity, in FDR of T2D has 
not been previously studied. There have however been some studies in FDR (young 
non-obese men) of T2D employing an extreme model of physical inactivity by bed 
rest. These studies reported that whole body and peripheral insulin sensitivity were not 
different but a greater increase in hepatic insulin resistance was evidenced in FDR as 
a result of reduced activity (Alibegovic et al., 2009). Further, changes in adipose tissue 
metabolism was not different in FDR (Alibegovic et al., 2010) but low grade 
inflammation which deteriorated to a greater extent was reported (Hojbjerre et al., 
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2011). These findings are equivocal but taken with the current data demonstrate some 
increased risk of physical inactivity in FDR. The current study identified no 
differences in whole body insulin sensitivity between the groups, post-prandial insulin 
AUC and free fatty acid AUC was greater in FDR which demonstrates reduced 
peripheral insulin sensitivity (confirmed by skeletal muscle insulin sensitivity index) 
with lesser suppression of peripheral lipolysis (confirmed by greater circulating 
NEFA) following ingestion of carbohydrate. Furthermore, HOMA-IR changes 
following inactivity were not significantly different between groups following 
inactivity but fasting insulin was increased to a greater extent in FDR and hepatic 
insulin resistance had a trend for FDR to exhibit an augmented response. It could be 
argued that the hepatic insulin resistance index derived from indices of the oral glucose 
tolerance test (OGTT) was not sensitive enough to detect small changes or differences 
between groups; the use of a hyperinsulinemic euglycemic clamp may have revealed 
another insight. However, taking into account previous research, hepatic insulin 
resistance is likely to be secondary to skeletal muscle.  
Moreover, FDR accumulated greater amounts of android fat and shown greater levels 
of fasting plasma triglycerides. All of the aforementioned have been strongly 
associated with the development of T2D (Aune et al., 2015, DeFronzo and Tripathy, 
2009, Després and Lemieux, 2006, Ferrannini et al., 1983) and should confirm the 
importance reducing sedentary time in strategies for the prevention of the disease.   
When considering inactivity-induced T2D, one plausible paradigm suggests that 
physical inactivity causes a reduction in skeletal muscle insulin sensitivity, 
contributing to a repartitioning of energy substrates into storage; increasing central fat 
accumulation and ectopic storage within the liver and other organs, causing further 
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insulin resistance (Jornayvaz et al., 2010, Rabol et al., 2011, Rector and Thyfault, 
2011, Petersen et al., 2007, DeFronzo and Tripathy, 2009). As peripheral insulin 
resistance progresses, continued ectopic fat accumulation within the liver and pancreas 
precipitates development of metabolic syndrome, a progressive decline in ß-cell 
function and ultimately T2D (Tan and Vidal-Puig, 2008). The data here supports this 
hypothesis and the early parts of this paradigm; however, precise mechanistic insight 
of this is yet to be established. The current and previous data (Krogh-Madsen et al., 
2010, Olsen et al., 2008) assessed the inactivity responses after 14 days only which 
provides no time-course of the mechanisms underlying these impairments. With step-
reduction and overfeeding, a reduction in insulin sensitivity was observed after 3 days 
with no change in VAT until day 14 (Knudsen et al., 2012). Molecular study has 
previously revealed that skeletal muscle insulin signalling is attenuated after reduced 
PA in humans (Krogh-Madsen et al., 2010) and rodents (Kump and Booth, 2005). 
Unravelling the sequelae of the combined metabolic and molecular changes would 
provide pathophysiological insight. Inactivity-induced changes are headed in a 
pathological direction (Thyfault and Krogh-Madsen, 2011), though it will be difficult 
to link acute changes to the development of chronic disease. Data from sedentary 
controls in clinical trials has shown that as little as 4-6 months of a physically inactive 
lifestyle causes metabolic deterioration (Patel et al., 2011).  However, administering 
mechanistic studies for much longer than 14 days would be ethically difficult. 
6.3 Resumption of habitual PA reversed all observed changes in both groups 
Small but significant and clinically relevant changes were induced by simply reducing 
(~80%) average daily steps and avoiding PA. Equally, these changes were reversed 
when habitual levels of PA and daily average steps were resumed. During the inactivity 
phase, the observed changes were induced by simply avoidance of PA (e.g. 
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taxis/public transport, using escalators/elevators, shopping online) and vice versa 
during resumption of habitual PA by engagement in PA (e.g. commuting by foot or 
bicycle, taking the stairs, shopping in store). A noteworthy point is that the participants 
involved did not substantially change their reality throughout (i.e. continued to work, 
care for dependants and study etc.); they were also non-exercisers and were not 
provided with any programme for resumption of activity. The effects observed here 
are as a result of simple habitual PA lifestyle changes where importantly, a reduction 
of energy demand in skeletal muscle has induced impairments associated with the 
development of T2D. Some authors will argue the changes observed were due to 
alterations in energy balance as opposed to PA. Nevertheless, dietary consumption did 
not change throughout the study so the changes observed relate to a state of positive 
energy balance derived from decreased energy expenditure rather than increased 
intake. Future research may wish to reduce energy intake during the inactive phase but 
then a concomitant dietary restriction will potentially introduce confounding effects.  
6.4 Public health message 
The public health message of this work is clear - minimise sedentary behaviour. The 
cross-sectional analysis of healthy versus unhealthy and non-obese versus obese 
phenotypes can be taken together with regression analysis relating domains of PA and 
liver fat to show that sedentary behaviour emerges as the most common domain of 
activity associated with a unfavourable health profile. The step-reduction intervention 
went on to show that physical inactivity induced detrimental changes in body 
composition (regional and organ specific fat), whole body insulin sensitivity and 
dyslipidaemia. Together these studies provide compelling evidence that sedentary time 
is an inherent aspect of a deteriorated cardiometabolic profile which could chronically 
lead to overt T2D. This thesis also reveals a profound link between physical inactivity 
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and cardiorespiratory fitness (CRF), which is an independent predictor of mortality 
risk  (Blair et al., 1989, Ekelund et al., 1988). Favourable health parameters have been 
associated with CRF in the findings of all data chapters. An unhealthy metabolic 
profile, a greater BMI and higher liver fat were all linked with low CRF in cross-
sectional analysis. The striking decrease in CRF following physical inactivity, 
provides robust evidence for a physically active lifestyle to maintain CRF, and thus 
optimal health status. Long standing public health messages have promoted exercise 
and yet adherence to said guidelines are poor. Perhaps it is time to move away from 
‘idealistic approaches’ (i.e. recommendations of moderate-vigorous PA) and adopt a 
‘compromising approach’ promoting subtle and sustainable changes to daily living 
(e.g. avoidance of sedentary behaviour and increased daily average steps as shown 
here). In an increasingly sedentary society, behavioural change and innovative 
strategies may be pivotal.  
6.5 Strengths and limitations 
The strengths and limitations have been discussed throughout this thesis along with 
future direction. To summarise, this work has a number of strengths including, 
objective monitoring of PA, comprehensive assessment of body composition including 
skeletal muscle and adipose region and organ specific, gold standard measurement of 
maximal oxygen consumption and validated measures of tissue-specific insulin 
sensitivity. A major additional strength is the novelty of the step-reduction intervention 
and the insight it has shed on the potential pathophysiology of physical inactivity. 
However, as discussed, further research is required. Moreover, are some additional 
noteworthy limitations, whilst the sample size is greater than that of previous research 
it is still somewhat small. Further, this research has not investigated other potentially 
pivotal changes that are associated with the development of T2D, such as pancreatic 
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fat or β-cell function. Of note, there are some cardiovascular measures (cIMT and 
FMD) that remain to be analysed in this cohort. To induce a step-reduction intervention 
for a substantially longer period would pose ethical challenges, however, there are 
some questions that remain within the realms of 14-28 days. Feasible study design 
could include investigating the effects of breaking up sedentary behaviour or increased 
sedentary behaviour without a concomitant decrease in physical activity. A dose-
response understanding of sedentary behaviour would be insightful, determining at 
which point these change become ‘irreversible’ would aid the provision of 
recommendations for acceptable levels of sedentary behaviour. 
6.6 Future direction  
The use of a short-term physical inactivity model provides a mechanistic basis for 
understanding the consequences of low PA and increased sedentary behaviour. 
Although this approach cannot be directly linked with chronic disease further 
investigation is warranted to unravel the pathological processes (Thyfault and Krogh-
Madsen, 2011). Future studies should determine the metabolic and molecular 
mechanisms considering inter-organ cross-talk between skeletal muscle, adipose tissue 
and liver. The immediate future direction of the current investigation is to examine the 
skeletal muscle and adipose tissue biopsies have already been obtained. Cells/tissues 
can modify their phenotype by changing the expression of key proteins (proteomic 
changes) through epigenetic regulation, a mechanism by which gene expression can 
be either activated or suppressed without affecting the DNA sequence (i.e. genotype). 
One such mechanism is through microRNAs that can influence the expression of many 
genes simultaneously, resulting in changes of the whole proteome and therefore 
functionality of the cells and tissues. These molecular investigations were postponed 
due to the time taken to accrue and analyse the data reported here.  
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Insulin has multiple metabolic functions that differ across organ systems. A multistage   
hyperinsulinemic euglycemic clamp would be insightful for future research so that 
simultaneous insulin action can be determined for skeletal muscle, adipose tissue and 
liver which would define the contribution and/or compensation of each. Moreover, if 
the observed metabolic changes originate primarily from inactivity-induced skeletal 
muscle insulin resistance, post-prandial muscle glucose uptake would be blunted 
which is associated with secondary changes in liver and adipose tissue. Thereby, 
excess glucose may diverted to the liver and converted to liver fat by de novo 
lipogenesis (DNL). With liver fat accumulation, more lipid is exported as VLDL-
triglyceride, accounting for the increased plasma triglyceride. These metabolic 
mechanisms are yet to be determined by induced physical inactivity in vivo. Future 
studies should i) determine whether short-term, low PA increases DNL leading to an 
accumulation of liver fat and ii) determine if very low density lipoprotein (VLDL) 
triglyceride production rates increase, secondary to this liver fat accumulation, causing 
hyperlipidaemia.  
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6.7 Conclusion 
Sedentary behaviour is independently associated with obesity and liver fat which are 
major risk factors for the development of T2D. Short-term sedentary behaviour, 
induced by a step-reduction model, leads to a decrease in cardiorespiratory fitness, 
central and liver fat accumulation, multi-organ insulin resistance and dyslipidaemia. 
These changes provides mechanistic insight into how chronic physical inactivity 
contributes to development of T2D but further research is required to determine how 
these changes arise. Importantly, the decompensation induced by inactivity are 
reversible with resumption of normal physical activity. These data must be used as a 
platform to develop guidelines and strategies aimed at preventing chronic physical 
inactivity and sedentary behaviour, particularly in FDR. Considering linked epidemics 
of physical inactivity and T2D new strategies must be developed to promote the 
importance of a habitually active lifestyle, either as a minimum or in addition to current 
guidelines. 
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Table 8.1 Demographics of those who had MRI versus those who did not (Chapter 3). 
 
 
 
 
 
 
 
 
 
 
 
 MRI (n=72) No-MRI (n=24) P value 
Gender 
M n=40; F n=32 M n=12; F n=14 0.135 
Age (years) 
40 (37, 43) 37 (32, 42) 0.335 
Weight (kg) 
77.5 (73.6, 81.4) 82.6 (76.0, 89.3) 0.181 
BMI (kg/m2) 
26.2 (25.1, 27.3) 27.8 (26.5, 31.1) 0.137 
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Figure 8.1 Association of absolute liver fat percentage (%) with A) daily average steps, B) sedentary time, C) light activity, D) moderate-vigorous 
activity, E) metabolic equivalents (METS) and F) V̇O2 peak. 
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Table 8.2 Univariate and multivariate regression for visceral adipose tissue (VAT) (Chapter 4). 
Data was transformed and analysed using 1og10; data presented here is back transformed to original units. BMI, body mass index; METS, metabolic 
equivalents; V̇O2 peak, cardiorespiratory fitness; MVPA, moderate-vigorous physical activity.  
 
 
 
 
 Univariate Multivariate 
β coefficient 95% CI P β coefficient 95% CI P  
Age (yrs) 1.03 1.01, 1.07 <0.0005 1.01 1.01, 1.04 0.031 
BMI (kg/m2) 1.11 1.03, 1.28 <0.0005 1.10 1.04, 1.26 <0.0005 
Steps (1,000) -0.94 -0.85, -0.95 0.027 -0.99 -0.94, 1.02 0.565 
Sedentary time (hr) 1.10 1.08, 1.31 0.023 1.10 1.04, 1.42 0.218 
METS (0.1) -0.94 -0.83, -0.94 0.044 -0.40 -0.37, -2.51 0.049 
V̇O2 peak (ml/kg/min) -0.96 -0.90, -0.98 <0.0005 -0.98 -0.95, 0.99 0.094 
Light activity (hr) -0.88 -0.69, -0.89 0.041 1.07 -0.99, 1.34 0.353 
Moderate activity (hr) -1.01 -0.87, 1.18 0.937 
Vigorous activity (hr) -0.79 -0.41, 0.96 0.275 
MVPA (hr) -0.99 -0.86, 1.10 0.840 
Lying time (hr) -1.00 -0.85, 1.15 0.947 
Sleep duration (hr) 1.02 -0.89, 1.23 0.769 
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Table 8.3 Univariate and multivariate regression for subcutaneous adipose tissue (SAT) (Chapter 4). 
BMI, body mass index; METS, metabolic equivalents; V̇O2 peak, cardiorespiratory fitness; MVPA, moderate-vigorous physical activity. 
 
 
 
 Univariate Multivariate 
β coefficient 95% CI P β coefficient 95% CI P  
Age (yrs) 0.070 -0.088, 0.227 0.379 -0.194 -0.323, -0.066 0.004 
BMI (kg/m2) 1.227 0.883, 1.570 <0.0005 1.188 0.780, 1.597 <0.0005 
Sedentary time (hr) 1.705 0.745, 2.665 0.001 0.082 -1.834, 1.998 0.932 
Light activity (hr) -2.216 -3.636, -0.769 0.003 -0.052 -1.888, 1.785 0.955 
METS (0.1) -1.374 -2.052, -6.957 <0.0005 -2.391 -13.520, 8.738 0.669 
V̇O2 peak (ml/kg/min) -0.563 -0.794, -0.332 <0.0005 -0.376 -0.612, -0.140 0.002 
Steps (1,000) -0.352 -0.980, 0.277 0.268 
Moderate activity (hr) -1.347 -3.224, 0.529 0.157 
Vigorous activity (hr) -4.864 -9.918, 0.191 0.059 
MVPA (hr) -1.334 -2.841, 0.173 0.082 
Lying time (hr) 0.918 -0.842, 2.678 0.302 
Sleep duration (hr) 1.490 -0.446, 3.425 0.129 
